ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS
1. NAME OF THE MEDICINAL PRODUCT

INTELENCE 25 mg tablets
INTELENCE 100 mg tablets
INTELENCE 200 mg tablets

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

INTELENCE 25 mg tablets
Each tablet contains 25 mg of etravirine.
Excipient with known effect: Each tablet contains 40 mg lactose.

INTELENCE 100 mg tablets
Each tablet contains 100 mg of etravirine.
Excipient with known effect: Each tablet contains 160 mg lactose.

INTELENCE 200 mg tablets
Each tablet contains 200 mg of etravirine.

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

INTELENCE 25 mg tablets
Tablet
White to off-white, oval, scored tablet, debossed with “TMC” on one side.
The tablet can be divided into equal doses.

INTELENCE 100 mg tablets
Tablet
White to off-white, oval tablet, debossed with “T125” on one side and “100” on the other side.

INTELENCE 200 mg tablets
Tablet
White to off-white, biconvex, oblong tablet debossed with “T200” on one side.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

INTELENCE, in combination with a boosted protease inhibitor and other antiretroviral medicinal products, is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-experienced adult patients and in antiretroviral treatment-experienced paediatric patients from 6 years of age (see sections 4.4, 4.5 and 5.1).

The indication in adults is based on week 48 analyses from 2 Phase III trials in highly pre-treated patients where INTELENCE was investigated in combination with an optimised background regimen (OBR) which included darunavir/ritonavir. The indication in paediatric patients is based on 48-week analyses of a single-arm, Phase II trial in antiretroviral treatment-experienced paediatric patients (see section 5.1).

4.2 Posology and method of administration

Therapy should be initiated by a physician experienced in the management of HIV infection.
INTELENCE must always be given in combination with other antiretroviral medicinal products.

Posology

Adults
The recommended dose of INTELENCE for adults is 200 mg (two 100 mg tablets) taken orally twice daily (b.i.d.), following a meal (see section 5.2).

Paediatric population (6 years to less than 18 years of age)
The recommended dose of INTELENCE for paediatric patients (6 years to less than 18 years of age and weighing at least 16 kg) is based on body weight (see table below). INTELENCE tablet(s) should be taken orally, following a meal (see section 5.2).

Recommended dose of INTELENCE for paediatric patients 6 years to less than 18 years of age

<table>
<thead>
<tr>
<th>Body weight</th>
<th>Dose</th>
<th>Tablets</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 16 to &lt; 20 kg</td>
<td>100 mg b.i.d.</td>
<td>four 25 mg tablets twice daily or one 100 mg tablet twice daily</td>
</tr>
<tr>
<td>≥ 20 to &lt; 25 kg</td>
<td>125 mg b.i.d.</td>
<td>five 25 mg tablets twice daily or one 100 mg tablet and one 25 mg tablet twice daily</td>
</tr>
<tr>
<td>≥ 25 to &lt; 30 kg</td>
<td>150 mg b.i.d.</td>
<td>six 25 mg tablets twice daily or one 100 mg tablet and two 25 mg tablets twice daily</td>
</tr>
<tr>
<td>≥ 30 kg</td>
<td>200 mg b.i.d.</td>
<td>eight 25 mg tablets twice daily or two 100 mg tablets twice daily or one 200 mg tablet twice daily</td>
</tr>
</tbody>
</table>

Missed dose
If the patient misses a dose of INTELENCE within 6 hours of the time it is usually taken, the patient should take it following a meal as soon as possible and then take the next dose at the regularly scheduled time. If a patient misses a dose by more than 6 hours of the time it is usually taken, the patient should not take the missed dose and simply resume the usual dosing schedule.

Elderly
There is limited information regarding the use of INTELENCE in patients > 65 years of age (see section 5.2), therefore caution should be used in this population.

Hepatic impairment
No dose adjustment is suggested in patients with mild or moderate hepatic impairment (Child-Pugh Class A or B); INTELENCE should be used with caution in patients with moderate hepatic impairment. The pharmacokinetics of etravirine have not been studied in patients with severe hepatic impairment (Child-Pugh Class C). Therefore, INTELENCE is not recommended in patients with severe hepatic impairment (see sections 4.4 and 5.2).

Renal impairment
No dose adjustment is required in patients with renal impairment (see section 5.2).

Paediatric population (less than 6 years of age)
The safety and efficacy of INTELENCE in children less than 6 years of age or weighing less than 16 kg have not yet been established (see section 5.2). No data are available.

Pregnancy and postpartum
Based on limited data available, no dose adjustment is required during pregnancy and postpartum (see section 5.2).

Method of administration
Oral use.
Patients should be instructed to swallow the tablet(s) whole with a liquid such as water. Patients who are unable to swallow the tablet(s) whole may disperse the tablet(s) in a glass of water. For instructions on dispersion of the medicinal product before administration, see section 6.6.

4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Co-administration with elbasvir/grazoprevir (see section 4.5).

4.4 Special warnings and precautions for use

While effective viral suppression with antiretroviral therapy has been proven to substantially reduce the risk of sexual transmission, a residual risk cannot be excluded. Precautions to prevent transmission should be taken in accordance with national guidelines.

INTELENCE should optimally be combined with other antiretrovirals that exhibit activity against the patient’s virus (see section 5.1).

A decreased virologic response to etravirine was observed in patients with viral strains harbouring 3 or more among the following mutations V90I, A98G, L100I, K101E/P, V106I, V179D/F, Y181C/I/V, and G190A/S (see section 5.1).

Conclusions regarding the relevance of particular mutations or mutational patterns are subject to change with additional data, and it is recommended to always consult current interpretation systems for analysing resistance test results.

No data other than drug-drug interaction data (see section 4.5) are available when etravirine is combined with raltegravir or maraviroc.

Severe cutaneous and hypersensitivity reactions

Severe cutaneous adverse drug reactions have been reported with INTELENCE; Stevens-Johnson Syndrome and erythema multiforme have been rarely (< 0.1%) reported. Treatment with INTELENCE should be discontinued if a severe cutaneous reaction develops.

The clinical data are limited and an increased risk of cutaneous reactions in patients with a history of NNRTI-associated cutaneous reactions cannot be excluded. Caution should be observed in such patients, especially in case of history of a severe cutaneous drug reaction.

Cases of severe hypersensitivity syndromes, including DRESS (Drug Rash with Eosinophilia and Systemic Symptoms) and TEN (toxic epidermal necrolysis), sometimes fatal, have been reported with the use of INTELENCE (see section 4.8). The DRESS syndrome is characterised by rash, fever, eosinophilia and systemic involvement (including, but not limited to, severe rash or rash accompanied by fever, general malaise, fatigue, muscle or joint aches, blisters, oral lesions, conjunctivitis, hepatitis and eosinophilia). Time to onset is usually around 3-6 weeks and the outcome in most cases is favourable upon discontinuation and after initiation of corticosteroid therapy.

Patients should be informed to seek medical advice if severe rash or hypersensitivity reactions occur. Patients who are diagnosed with a hypersensitivity reaction whilst on therapy must discontinue INTELENCE immediately.

Delay in stopping INTELENCE treatment after the onset of severe rash may result in a life-threatening reaction. Patients who have stopped treatment due to hypersensitivity reactions should not restart therapy with INTELENCE.
Rash
Rash has been reported with INTELENCE. Most frequently, rash was mild to moderate, occurred in
the second week of therapy, and was infrequent after week 4. Rash was mostly self-limiting and
generally resolved within 1 to 2 weeks on continued therapy. When prescribing INTELENCE to
females, prescribers should be aware that the incidence of rash was higher in females (see section 4.8).

Elderly
Experience in geriatric patients is limited: in the Phase III trials, 6 patients aged 65 years or older and
53 patients aged 56-64 years received INTELENCE. The type and incidence of adverse reactions in
patients > 55 years of age were similar to the ones in younger patients (see sections 4.2 and 5.2).

Pregnancy
Given the increased etravirine exposure during pregnancy, caution should be applied for those
pregnant patients that require concomitant medications or have comorbidities that may further increase
etravirine exposure.

Patients with coexisting conditions
Hepatic impairment
Etravirine is primarily metabolised and eliminated by the liver and highly bound to plasma proteins.
Effects on unbound exposure could be expected (has not been studied) and therefore caution is advised
in patients with moderate hepatic impairment. INTELENCE has not been studied in patients with
severe hepatic impairment (Child-Pugh Class C) and its use is therefore not recommended in this
group of patients (see sections 4.2 and 5.2).

Co-infection with HBV (hepatitis B virus) or HCV (hepatitis C virus)
Caution should be exercised in patients co-infected with hepatitis B or C virus due to the current
limited data available. A potential increased risk of liver enzymes increase cannot be excluded.

Weight and metabolic parameters
An increase in weight and in levels of blood lipids and glucose may occur during antiretroviral
therapy. Such changes may in part be linked to disease control and life style. For lipids, there is in
some cases evidence for a treatment effect, while for weight gain there is no strong evidence relating
this to any particular treatment. For monitoring of blood lipids and glucose reference is made to
established HIV treatment guidelines. Lipid disorders should be managed as clinically appropriate.

Immune reconstitution syndrome
In HIV infected patients with severe immune deficiency at the time of initiation of CART, an
inflammatory reaction to asymptomatic or residual opportunistic pathogens may arise and cause
serious clinical conditions, or aggravation of symptoms. Typically, such reactions have been observed
within the first weeks or months of initiation of CART. Relevant examples are cytomegalovirus
retinitis, generalised and/or focal mycobacterial infections and Pneumocystis jiroveci pneumonia. Any
inflammatory symptoms should be evaluated and treatment instituted when necessary.

Autoimmune disorders (such as Graves' disease) have also been reported to occur in the setting of
immune reactivation; however, the reported time to onset is more variable and these events can occur
many months after initiation of treatment (see section 4.8).

Osteonecrosis
Although the aetiology is considered to be multifactorial (including corticosteroid use, alcohol
consumption, severe immunosuppression, higher body mass index), cases of osteonecrosis have been
reported particularly in patients with advanced HIV disease and/or long-term exposure to CART.
Patients should be advised to seek medical advice if they experience joint aches and pain, joint
stiffness or difficulty in movement.
Interactions with medicinal products

It is not recommended to combine etravirine with tipranavir/ritonavir, due to a marked pharmacokinetic interaction (76% decrease of etravirine AUC) that could significantly impair the virologic response to etravirine.

The combination of etravirine with simeprevir, daclatasvir, atazanavir/cobicistat or darunavir/cobicistat is not recommended (see section 4.5).

For further information on interactions with medicinal products see section 4.5.

Lactose intolerance and lactase deficiency

INTELENCE 25 mg tablets
Each tablet contains 40 mg of lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.

INTELENCE 100 mg tablets
Each tablet contains 160 mg of lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.

4.5 Interaction with other medicinal products and other forms of interaction

Medicinal products that affect etravirine exposure

Etravirine is metabolised by CYP3A4, CYP2C9 and CYP2C19 followed by glucuronidation of the metabolites by uridine diphosphate glucuronosyl transferase (UDPGT). Medicinal products that induce CYP3A4, CYP2C9 or CYP2C19 may increase the clearance of etravirine, resulting in lowered plasma concentrations of etravirine.

Co-administration of INTELENCE and medicinal products that inhibit CYP3A4, CYP2C9 or CYP2C19 may decrease the clearance of etravirine and may result in increased plasma concentrations of etravirine.

Medicinal products that are affected by the use of etravirine

Etravirine is a weak inducer of CYP3A4. Co-administration of INTELENCE with medicinal products primarily metabolised by CYP3A4 may result in decreased plasma concentrations of such medicinal products, which could decrease or shorten their therapeutic effects.

Etravirine is a weak inhibitor of CYP2C9 and CYP2C19. Etravirine is also a weak inhibitor of P-glycoprotein. Co-administration with medicinal products primarily metabolised by CYP2C9 or CYP2C19, or transported by P-glycoprotein, may result in increased plasma concentrations of such medicinal products, which could increase or prolong their therapeutic effect or alter their adverse events profile.

Known and theoretical interactions with selected antiretrovirals and non-antiretroviral medicinal products are listed in table 1. The table is not all-inclusive.

Interaction table

Interactions between etravirine and co-administered medicinal products are listed in table 1 (increase is indicated as “↑”, decrease as “↓”, no change as “↔”, not done as “ND”, confidence interval as “CI”).
<table>
<thead>
<tr>
<th>Medicinal products by therapeutic areas</th>
<th>Effects on drug levels</th>
<th>Recommendations concerning co-administration</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ANTI-INFECTIVES</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Antiretrovirals</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>NRTIs</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Didanosine 400 mg once daily</td>
<td>didanosine</td>
<td>No significant effect on didanosine and etravirine PK parameters is seen. INTELENCE and didanosine can be used without dose adjustments.</td>
</tr>
<tr>
<td></td>
<td>AUC ↔ 0.99 (0.79-1.25)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>C_{min} ND</td>
<td></td>
</tr>
<tr>
<td></td>
<td>C_{max} ↔ 0.91 (0.58-1.42)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>etravirine</td>
<td></td>
</tr>
<tr>
<td></td>
<td>AUC ↔ 1.11 (0.99-1.25)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>C_{min} ↔ 1.05 (0.93-1.18)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>C_{max} ↔ 1.16 (1.02-1.32)</td>
<td></td>
</tr>
<tr>
<td>Tenofovir disoproxil 245 mg once daily</td>
<td>tenofovir</td>
<td>No significant effect on tenofovir and etravirine PK parameters is seen. INTELENCE and tenofovir can be used without dose adjustments.</td>
</tr>
<tr>
<td></td>
<td>AUC ↔ 1.15 (1.09-1.21)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>C_{min} ↑ 1.19 (1.13-1.26)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>C_{max} ↑ 1.15 (1.04-1.27)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>etravirine</td>
<td></td>
</tr>
<tr>
<td></td>
<td>AUC ↓ 0.81 (0.75-0.88)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>C_{min} ↓ 0.82 (0.73-0.91)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>C_{max} ↓ 0.81 (0.75-0.88)</td>
<td></td>
</tr>
<tr>
<td>Other NRTIs</td>
<td>Not studied, but no interaction expected based on the primary renal elimination route for other NRTIs (e.g., abacavir, emtricitabine, lamivudine, stavudine and zidovudine).</td>
<td>Etravirine can be used with these NRTIs without dose adjustment.</td>
</tr>
<tr>
<td><strong>NNRTIs</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Efavirenz</td>
<td></td>
<td>It is not recommended to co-administer INTELENCE with other NNRTIs.</td>
</tr>
<tr>
<td>Nevirapine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rilpivirine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Combining two NNRTIs has not been shown to be beneficial. Concomitant use of INTELENCE with efavirenz or nevirapine may cause a significant decrease in the plasma concentration of etravirine and loss of therapeutic effect of INTELENCE. Concomitant use of INTELENCE with rilpivirine may cause a decrease in the plasma concentration of rilpivirine and loss of therapeutic effect of rilpivirine.</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>HIV Protease Inhibitors (PIs) - Unboosted (i.e. without co-administration of low-dose ritonavir)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Indinavir</td>
<td></td>
<td>It is not recommended to co-administer INTELENCE with indinavir.</td>
</tr>
<tr>
<td>Concomitant use of INTELENCE with indinavir may cause a significant decrease in the plasma concentration of indinavir and loss of therapeutic effect of indinavir.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nelfinavir</td>
<td></td>
<td>It is not recommended to co-administer INTELENCE with nelfinavir.</td>
</tr>
<tr>
<td>Not studied. INTELENCE is expected to increase nelfinavir plasma concentrations.</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>HIV PIs - Boosted with low-dose ritonavir</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Atazanavir/ritonavir 300/100 mg once daily</td>
<td>atazanavir</td>
<td>INTELENCE and atazanavir/ritonavir can be used without dose adjustment.</td>
</tr>
<tr>
<td>AUC ↓ 0.86 (0.79-0.93)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>C_{min} ↓ 0.62 (0.55-0.71)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>C_{max} ↔ 0.97 (0.89-1.05)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>etravirine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AUC ↑ 1.30 (1.18-1.44)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>C_{min} ↑ 1.26 (1.12-1.42)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>C_{max} ↑ 1.30 (1.17-1.44)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drug Combination</td>
<td>Drug</td>
<td>AUC</td>
</tr>
<tr>
<td>-----------------------------------------</td>
<td>--------------------</td>
<td>---------------------------</td>
</tr>
<tr>
<td>Darunavir/ritonavir 600/100 mg twice daily</td>
<td>Darunavir</td>
<td>$1.15 (1.05-1.26)$</td>
</tr>
<tr>
<td>Fosamprenavir/ritonavir 700/100 mg twice daily</td>
<td>Amprenavir</td>
<td>$1.69 (1.53-1.86)$</td>
</tr>
<tr>
<td>Lopinavir/ritonavir (tablet) 400/100 mg twice daily</td>
<td>Lopinavir</td>
<td>$0.87 (0.83-0.92)$</td>
</tr>
<tr>
<td>Saquinavir/ritonavir 1,000/100 mg twice daily</td>
<td>Saquinavir</td>
<td>$0.95 (0.64-1.42)$</td>
</tr>
<tr>
<td>Tipranavir/ritonavir 500/200 mg twice daily</td>
<td>Tipranavir</td>
<td>$1.18 (1.03-1.36)$</td>
</tr>
</tbody>
</table>

**HIV PIs – Boosted with cobicistat**

<table>
<thead>
<tr>
<th>Drug Combination</th>
<th>Drug</th>
<th>AUC</th>
<th>Cmin</th>
<th>Cmax</th>
<th>Etravirine AUC</th>
<th>Cmin</th>
<th>Cmax</th>
<th>Etravirine AUC</th>
<th>Cmin</th>
<th>Cmax</th>
</tr>
</thead>
<tbody>
<tr>
<td>Atazanavir/cobicistat</td>
<td>Darunavir/ritonavir</td>
<td>$0.47 (0.38-0.58)$</td>
<td>$0.61 (0.53-0.71)$</td>
<td>$0.40 (0.28-0.57)$</td>
<td>$0.97 (0.84-1.14)$</td>
<td>$1.08 (0.98-1.19)$</td>
<td>$1.05 (0.95-1.17)$</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Maraviroc/ritonavir 150/600/100 mg twice daily</td>
<td>Maraviroc</td>
<td>$3.10 (2.57-3.74)$</td>
<td>$2.72 (2.22-3.24)$</td>
<td>$2.57 (2.07-3.11)$</td>
<td>$1.77 (1.20-2.60)$</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The recommended dose for maraviroc when combined with INTELENCE in the presence of potent CYP3A inhibitors (e.g. boosted PIs) is 150 mg b.i.d. except for fosamprenavir/ritonavir (maraviroc dose 300 mg b.i.d.). No dose adjustment for INTELENCE is necessary. See also section 4.4.

Co-administration of INTELENCE with atazanavir/cobicistat or darunavir/ritonavir/cobicistat may decrease plasma concentrations of the PI and/or cobicistat, which may result in loss of therapeutic effect and development of resistance.

Co-administration of INTELENCE with atazanavir/cobicistat or darunavir/ritonavir/cobicistat is not recommended.

**CCR5 Antagonists**

<table>
<thead>
<tr>
<th>Drug Combination</th>
<th>Drug</th>
<th>AUC</th>
<th>Cmin</th>
<th>Cmax</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maraviroc 300 mg twice daily</td>
<td>Maraviroc</td>
<td>$0.47 (0.38-0.58)$</td>
<td>$0.61 (0.53-0.71)$</td>
<td>$0.40 (0.28-0.57)$</td>
</tr>
<tr>
<td>Maraviroc/darunavir/ritonavir 150/600/100 mg twice daily</td>
<td>Maraviroc*</td>
<td>$3.10 (2.57-3.74)$</td>
<td>$2.72 (2.22-3.24)$</td>
<td>$2.57 (2.07-3.11)$</td>
</tr>
</tbody>
</table>

* compared to maraviroc 150 mg b.i.d.
### Fusion Inhibitors

<table>
<thead>
<tr>
<th>Drug</th>
<th>Etravirine Effect</th>
<th>Notes</th>
</tr>
</thead>
</table>
| Enfuvirtide 90 mg twice daily | AUC ↔, C0 ↔, Cmax ↔ | Etravirine concentrations not studied and no effect is expected. *
|                     |                  | * based on population pharmacokinetic analyses                        |

### Integrase Strand Transfer Inhibitors

<table>
<thead>
<tr>
<th>Drug</th>
<th>Etravirine Effect</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dolutegravir 50 mg once daily</td>
<td>AUC ↓ 0.29 (0.26-0.34), Cmin ↓ 0.12 (0.09-0.16), Cmax ↓ 0.48 (0.43-0.54)</td>
<td>Etravirine significantly reduced plasma concentrations of dolutegravir. The effect of etravirine on dolutegravir plasma concentrations was mitigated by co-administration of darunavir/ritonavir or lopinavir/ritonavir, and is expected to be mitigated by atazanavir/ritonavir. <strong>INTELENCE should only be used with dolutegravir when co-administered with atazanavir/ritonavir, darunavir/ritonavir, or lopinavir/ritonavir. This combination can be used without dose adjustment.</strong></td>
</tr>
<tr>
<td>Dolutegravir + darunavir/ritonavir 50 mg once daily + 600/100 mg twice daily</td>
<td>AUC ↓ 0.75 (0.69-0.81), Cmin ↓ 0.63 (0.52-0.77), Cmax ↓ 0.88 (0.78-1.00)</td>
<td><strong>INTELENCE should only be used with dolutegravir when co-administered with atazanavir/ritonavir, darunavir/ritonavir, or lopinavir/ritonavir. This combination can be used without dose adjustment.</strong></td>
</tr>
<tr>
<td>Dolutegravir + Lopinavir/ritonavir 50 mg once daily + 400/100 mg twice daily</td>
<td>AUC ↓ 1.11 (1.02-1.20), Cmin ↑ 1.28 (1.13-1.45), Cmax ↑ 1.07 (1.02-1.13)</td>
<td><strong>INTELENCE and raltegravir can be used without dose adjustments.</strong></td>
</tr>
<tr>
<td>Raltegravir 400 mg twice daily</td>
<td>AUC ↓ 0.90 (0.68-1.18), Cmin ↓ 0.66 (0.34-1.26), Cmax ↓ 0.89 (0.68-1.15)</td>
<td><strong>INTELENCE and raltegravir can be used without dose adjustments.</strong></td>
</tr>
</tbody>
</table>

### ANTIARRHYTHMICS

<table>
<thead>
<tr>
<th>Drug</th>
<th>Etravirine Effect</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Digoxin 0.5 mg single dose</td>
<td>AUC ↑ 1.18 (0.90-1.56), C0 ND, Cmax ↑ 1.19 (0.96-1.49)</td>
<td><strong>INTELENCE and digoxin can be used without dose adjustments. It is recommended that digoxin levels be monitored when digoxin is combined with INTELENCE.</strong></td>
</tr>
<tr>
<td>Amiodarone Bepridil Disopyramide Flecainide Lidocaine (systemic) Mexiletine Propafenone Quinidine</td>
<td>Not studied. INTELENCE is expected to decrease plasma concentrations of these antiarrhythmics.</td>
<td>Caution is warranted and therapeutic concentration monitoring, if available, is recommended for antiarrhythmics when co-administered with INTELENCE.</td>
</tr>
<tr>
<td>ANTIBIOTICS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----------------</td>
<td>------------------------------</td>
<td>------------------------------</td>
</tr>
<tr>
<td>Azithromycin</td>
<td>Not studied. Based on the biliary elimination pathway of azithromycin, no drug interactions are expected between azithromycin and INTELENCE.</td>
<td></td>
</tr>
<tr>
<td>Clarithromycin</td>
<td>clarithromycin</td>
<td></td>
</tr>
<tr>
<td>500 mg twice daily</td>
<td>14-OH-clarithromycin</td>
<td></td>
</tr>
<tr>
<td></td>
<td>AUC ↓ 0.61 (0.53-0.69)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>C&lt;sub&gt;min&lt;/sub&gt; ↓ 0.47 (0.38-0.57)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>C&lt;sub&gt;max&lt;/sub&gt; ↓ 0.66 (0.57-0.77)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>AUC ↑ 1.21 (1.05-1.39)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>C&lt;sub&gt;min&lt;/sub&gt; ↑ 1.05 (0.90-1.22)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>C&lt;sub&gt;max&lt;/sub&gt; ↑ 1.33 (1.13-1.56)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>etravirine</td>
<td></td>
</tr>
<tr>
<td></td>
<td>AUC ↑ 1.42 (1.34-1.50)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>C&lt;sub&gt;min&lt;/sub&gt; ↑ 1.46 (1.36-1.58)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>C&lt;sub&gt;max&lt;/sub&gt; ↑ 1.46 (1.38-1.56)</td>
<td></td>
</tr>
<tr>
<td>ANTICOAGULANTS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Warfarin</td>
<td>Not studied. INTELENCE is expected to increase plasma concentrations of warfarin.</td>
<td></td>
</tr>
<tr>
<td>ANTICONVULSANTS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Carbamazepine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phenobarbital</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phenytoin</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ANTIFUNGALS</td>
<td>fluconazole</td>
<td></td>
</tr>
<tr>
<td>Fluconazole</td>
<td>AUC ↔ 0.94 (0.88-1.01)</td>
<td></td>
</tr>
<tr>
<td>200 mg once in the morning</td>
<td>C&lt;sub&gt;min&lt;/sub&gt; ↔ 0.91 (0.84-0.98)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>C&lt;sub&gt;max&lt;/sub&gt; ↔ 0.92 (0.85-1.00)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>etravirine</td>
<td></td>
</tr>
<tr>
<td></td>
<td>AUC ↑ 1.86 (1.73-2.00)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>C&lt;sub&gt;min&lt;/sub&gt; ↑ 2.09 (1.90-2.31)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>C&lt;sub&gt;max&lt;/sub&gt; ↑ 1.75 (1.60-1.91)</td>
<td></td>
</tr>
<tr>
<td>Itraconazole</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ketoconazole</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Posaconazole</td>
<td>Not studied. Posaconazole, a potent inhibitor of CYP3A4, may increase plasma concentrations of etravirine. Itraconazole and ketoconazole are potent inhibitors as well as substrates of CYP3A4. Concomitant systemic use of itraconazole or ketoconazole and INTELENCE may increase plasma concentrations of etravirine. Simultaneously, plasma concentrations of itraconazole or ketoconazole may be decreased by INTELENCE.</td>
<td></td>
</tr>
<tr>
<td>Voriconazole</td>
<td>voriconazole</td>
<td></td>
</tr>
<tr>
<td>200 mg twice daily</td>
<td>AUC ↑ 1.14 (0.88-1.47)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>C&lt;sub&gt;min&lt;/sub&gt; ↑ 1.23 (0.87-1.75)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>C&lt;sub&gt;max&lt;/sub&gt; ↓ 0.95 (0.75-1.21)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>etravirine</td>
<td></td>
</tr>
<tr>
<td></td>
<td>AUC ↑ 1.36 (1.25-1.47)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>C&lt;sub&gt;min&lt;/sub&gt; ↑ 1.52 (1.41-1.64)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>C&lt;sub&gt;max&lt;/sub&gt; ↑ 1.26 (1.16-1.38)</td>
<td></td>
</tr>
</tbody>
</table>
### ANTIMALARIALS

<table>
<thead>
<tr>
<th>Drug</th>
<th>AUC</th>
<th>C min</th>
<th>C max</th>
</tr>
</thead>
<tbody>
<tr>
<td>Artemether/Lumefantrine</td>
<td>↓ 0.62</td>
<td>↓ 0.82</td>
<td>↓ 0.72</td>
</tr>
<tr>
<td></td>
<td>(0.48-0.80)</td>
<td>(0.67-1.01)</td>
<td>(0.55-0.94)</td>
</tr>
<tr>
<td>Dihydroartemisinin</td>
<td>↓ 0.85</td>
<td>↓ 0.83</td>
<td>↓ 0.84</td>
</tr>
<tr>
<td></td>
<td>(0.75-0.97)</td>
<td>(0.71-0.97)</td>
<td>(0.71-0.99)</td>
</tr>
<tr>
<td>Lumefantrine</td>
<td>↓ 0.87</td>
<td>↓ 0.97</td>
<td>↓ 1.07</td>
</tr>
<tr>
<td></td>
<td>(0.77-0.98)</td>
<td>(0.83-1.15)</td>
<td>(0.94-1.23)</td>
</tr>
<tr>
<td>Etravirine</td>
<td>↔ 1.10</td>
<td>↔ 1.08</td>
<td>↔ 1.11</td>
</tr>
<tr>
<td></td>
<td>(1.06-1.15)</td>
<td>(1.04-1.14)</td>
<td>(1.06-1.17)</td>
</tr>
</tbody>
</table>

Close monitoring of antimalarial response is warranted when co-administering INTELENCE and antimalarials as a significant decrease in exposure of antimalarials may result in decreased antimalarial efficacy. No dose adjustment is needed for INTELENCE.

### ANTIMYCOBACTERIALS

<table>
<thead>
<tr>
<th>Drug</th>
<th>AUC</th>
<th>C min</th>
<th>C max</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rifampicin</td>
<td>↓ 0.83</td>
<td>↓ 0.76</td>
<td>↓ 0.90</td>
</tr>
<tr>
<td></td>
<td>(0.75-0.94)</td>
<td>(0.66-0.87)</td>
<td>(0.78-1.03)</td>
</tr>
<tr>
<td>Rifapentine</td>
<td>↓ 0.83</td>
<td>↓ 0.78</td>
<td>↓ 0.85</td>
</tr>
<tr>
<td></td>
<td>(0.74-0.92)</td>
<td>(0.70-0.87)</td>
<td>(0.72-1.00)</td>
</tr>
<tr>
<td>Etravirine</td>
<td>↓ 0.63</td>
<td>↓ 0.65</td>
<td>↓ 0.63</td>
</tr>
<tr>
<td></td>
<td>(0.54-0.74)</td>
<td>(0.56-0.74)</td>
<td>(0.53-0.74)</td>
</tr>
</tbody>
</table>

Rifampicin and rifapentine are expected to decrease plasma concentrations of etravirine. INTELENCE should be used in combination with a boosted PI. Rifampicin is contraindicated in combination with boosted PIs.

### BENZODIAZEPINES

<table>
<thead>
<tr>
<th>Drug</th>
<th>AUC</th>
<th>C min</th>
<th>C max</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diazepam</td>
<td>↓ 0.82</td>
<td>↓ 0.76</td>
<td>↓ 0.90</td>
</tr>
<tr>
<td></td>
<td>(0.66-0.87)</td>
<td>(0.78-1.03)</td>
<td></td>
</tr>
</tbody>
</table>

Etravirine is expected to increase plasma concentrations of diazepam. Alternatives to diazepam should be considered.

### CORTICOSTEROIDS

<table>
<thead>
<tr>
<th>Drug</th>
<th>AUC</th>
<th>C min</th>
<th>C max</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dexamethasone (systemic)</td>
<td>↓ 0.63</td>
<td>↓ 0.65</td>
<td>↓ 0.63</td>
</tr>
<tr>
<td></td>
<td>(0.54-0.74)</td>
<td>(0.56-0.74)</td>
<td>(0.53-0.74)</td>
</tr>
</tbody>
</table>

Systemic dexamethasone should be used with caution or alternatives should be considered, particularly for chronic use.
**OESTROGEN-BASED CONTRACEPTIVES**

<table>
<thead>
<tr>
<th>Ethinylestradiol</th>
<th>0.035 mg once daily</th>
<th>Ethinylestradiol</th>
<th>AUC ↑ 1.22 (1.13-1.31)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>C&lt;sub&gt;min&lt;/sub&gt; ↔ 1.09 (1.01-1.18)</td>
</tr>
<tr>
<td></td>
<td>Norethindrone</td>
<td>norethindrone</td>
<td>C&lt;sub&gt;max&lt;/sub&gt; ↑ 1.33 (1.21-1.46)</td>
</tr>
<tr>
<td>1 mg once daily</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>C&lt;sub&gt;min&lt;/sub&gt; ± 0.76 (0.63-0.90)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>etravirine</td>
<td>C&lt;sub&gt;max&lt;/sub&gt; ↑ 1.05 (0.98-1.12)</td>
</tr>
</tbody>
</table>

The combination of oestrogen- and/or progesterone-based contraceptives and INTELENCE can be used without dose adjustment.

**HEPATITIS C VIRUS (HCV) DIRECT-ACTING ANTIVIRALS**

<table>
<thead>
<tr>
<th>Ribavirin</th>
<th>Not studied, but no interaction expected based on the renal elimination pathway of ribavirin.</th>
<th>The combination of INTELENCE and ribavirin can be used without dose adjustments.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Boceprevir</td>
<td>boceprevir</td>
<td>The clinical significance of the reductions in etravirine pharmacokinetic parameters and boceprevir C&lt;sub&gt;min&lt;/sub&gt; in the setting of the combination therapy with HIV antiretroviral medicines which also affect the pharmacokinetics of etravirine and/or boceprevir has not been directly assessed. Increased clinical and laboratory monitoring for HIV and HCV suppression is recommended.</td>
</tr>
<tr>
<td>800 mg 3 times daily + etravirine 200 mg every 12 hours</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>boceprevir</td>
<td></td>
</tr>
<tr>
<td></td>
<td>AUC ↑ 1.10 (0.94-1.28)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>C&lt;sub&gt;max&lt;/sub&gt; ↑ 1.10 (0.94-1.29)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>C&lt;sub&gt;min&lt;/sub&gt; 0.88 (0.66-1.17)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>etravirine</td>
<td></td>
</tr>
<tr>
<td></td>
<td>AUC ↓ 0.77 (0.66-0.91)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>C&lt;sub&gt;max&lt;/sub&gt; 0.76 (0.68-0.85)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>C&lt;sub&gt;min&lt;/sub&gt; 0.71 (0.54-0.95)</td>
<td></td>
</tr>
</tbody>
</table>

**HERBAL PRODUCTS**

| St John's wort (Hypericum perforatum) | Not studied. St John’s wort is expected to decrease the plasma concentrations of etravirine. | Co-administration of INTELENCE and etravirine is not recommended. |

**HMG CO-A REDUCTASE INHIBITORS**

<table>
<thead>
<tr>
<th>Atorvastatin</th>
<th>40 mg once daily</th>
<th>atorvastatin</th>
<th>AUC ↓ 0.63 (0.58-0.68)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>C&lt;sub&gt;min&lt;/sub&gt; ND</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>C&lt;sub&gt;max&lt;/sub&gt; ↑ 1.04 (0.84-1.30)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>2-OH-atorvastatin</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>AUC ↑ 1.27 (1.19-1.36)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>C&lt;sub&gt;min&lt;/sub&gt; ND</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>C&lt;sub&gt;max&lt;/sub&gt; ↑ 1.76 (1.60-1.94)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>etravirine</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>AUC ↔ 1.02 (0.97-1.07)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>C&lt;sub&gt;min&lt;/sub&gt; 1.10 (1.02-1.19)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>C&lt;sub&gt;max&lt;/sub&gt; ↔ 0.97 (0.93-1.02)</td>
<td></td>
</tr>
</tbody>
</table>

The combination of INTELENCE and atorvastatin can be given without any dose adjustments, however, the dose of atorvastatin may need to be altered based on clinical response.
<table>
<thead>
<tr>
<th>Drug</th>
<th>Study Details</th>
<th>INTELENCE Dosage</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fluvastatin, Lovastatin, Pravastatin, Rosuvastatin, Simvastatin</td>
<td>Not studied. No interaction between pravastatin and INTELENCE is expected. Lovastatin, rosuvastatin and simvastatin are CYP3A4 substrates and co-administration with INTELENCE may result in lower plasma concentrations of the HMG Co-A reductase inhibitor. Fluvastatin, and rosuvastatin are metabolised by CYP2C9 and co-administration with INTELENCE may result in higher plasma concentrations of the HMG Co-A reductase inhibitor.</td>
<td></td>
<td>Dose adjustments for these HMG Co-A reductase inhibitors may be necessary.</td>
</tr>
</tbody>
</table>

### H₂-RECEPTOR ANTAGONISTS

<table>
<thead>
<tr>
<th>Drug</th>
<th>INTELENCE Dosage</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ranitidine</td>
<td>150 mg twice daily</td>
<td>etravirine AUC ↓ 0.86 (0.76-0.97) C&lt;sub&gt;min&lt;/sub&gt; ND C&lt;sub&gt;max&lt;/sub&gt; ↓ 0.94 (0.75-1.17)</td>
</tr>
</tbody>
</table>

### IMMUNOSUPPRESSANTS

<table>
<thead>
<tr>
<th>Drug</th>
<th>INTELENCE Dosage</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cyclosporin, Sirolimus, Tacrolimus</td>
<td>Not studied. Etravirine is expected to decrease plasma concentrations of cyclosporine, sirolimus and tacrolimus.</td>
<td>Co-administration with systemic immunosuppressants should be done with caution because plasma concentrations of cyclosporine, sirolimus and tacrolimus may be affected when co-administered with INTELENCE.</td>
</tr>
</tbody>
</table>

### NARCOTIC ANALGESICS

<table>
<thead>
<tr>
<th>Drug</th>
<th>INTELENCE Dosage</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methadone</td>
<td>Individual dose ranging from 60 mg to 130 mg once daily</td>
<td>R(-) methadone AUC ↔ 1.06 (0.99-1.13) C&lt;sub&gt;min&lt;/sub&gt; ↔ 1.10 (1.02-1.19) C&lt;sub&gt;max&lt;/sub&gt; ↔ 1.02 (0.96-1.09) S(+) methadone AUC ↔ 0.89 (0.82-0.96) C&lt;sub&gt;min&lt;/sub&gt; ↔ 0.89 (0.81-0.98) C&lt;sub&gt;max&lt;/sub&gt; ↔ 0.89 (0.83-0.97) Etravirine AUC ↔ a C&lt;sub&gt;min&lt;/sub&gt; ↔ a C&lt;sub&gt;max&lt;/sub&gt; ↔ a</td>
</tr>
</tbody>
</table>

### PHOSPHODIESTERASE, TYPE 5 (PDE-5) INHIBITORS

<table>
<thead>
<tr>
<th>Drug</th>
<th>INTELENCE Dosage</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sildenafil 50 mg single dose</td>
<td></td>
<td>Etravirine AUC ↓ 0.43 (0.36-0.51) C&lt;sub&gt;min&lt;/sub&gt; ND C&lt;sub&gt;max&lt;/sub&gt; ↓ 0.55 (0.40-0.75) N-desmethyl-sildenafil AUC ↓ 0.59 (0.52-0.68) C&lt;sub&gt;min&lt;/sub&gt; ND C&lt;sub&gt;max&lt;/sub&gt; ↓ 0.75 (0.59-0.96)</td>
</tr>
</tbody>
</table>

### PLATELET AGGREGATION INHIBITORS

<table>
<thead>
<tr>
<th>Drug</th>
<th>INTELENCE Dosage</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clopidogrel</td>
<td></td>
<td>In vitro data show that etravirine has inhibitory properties on CYP2C19. It is therefore possible that etravirine may inhibit the metabolism of clopidogrel to its active metabolite by such inhibition of CYP2C19 in vivo. The clinical relevance of this interaction has not been demonstrated.</td>
</tr>
</tbody>
</table>

### PROTON PUMP INHIBITORS

<table>
<thead>
<tr>
<th>Drug</th>
<th>INTELENCE Dosage</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Omeprazole</td>
<td>40 mg once daily</td>
<td>Etravirine AUC ↑ 1.41 (1.22-1.62) C&lt;sub&gt;min&lt;/sub&gt; ND C&lt;sub&gt;max&lt;/sub&gt; ↑ 1.17 (0.96-1.43)</td>
</tr>
</tbody>
</table>
SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS)

<table>
<thead>
<tr>
<th>Paroxetine</th>
<th>Paroxetine</th>
</tr>
</thead>
<tbody>
<tr>
<td>20 mg once daily</td>
<td></td>
</tr>
</tbody>
</table>

- **paroxetine**
  - AUC ↔ 1.03 (0.90-1.18)
  - C\text{min} ↓ 0.87 (0.75-1.02)
  - C\text{max} ↔ 1.06 (0.95-1.20)

- **etravirine**
  - AUC ↔ 1.01 (0.93-1.10)
  - C\text{min} ↔ 1.07 (0.98-1.17)
  - C\text{max} ↔ 1.05 (0.96-1.15)

INTELENCE can be co-administered with paroxetine without dose adjustments.

\[a\] Comparison based on historic control.

\[b\] Study was conducted with tenofovir disoproxil fumarate 300 mg once daily

Note: In drug-drug interaction studies, different formulations and/or doses of etravirine were used which led to similar exposures and, therefore, interactions relevant for one formulation are relevant for the other.

---

**Paediatric population**

Interaction studies have only been performed in adults.

**4.6 Fertility, pregnancy and lactation**

**Pregnancy**

As a general rule, when deciding to use antiretroviral agents for the treatment of HIV infection in pregnant women, and consequently for reducing the risk of HIV vertical transmission to the newborn, the animal data as well as the clinical experience in pregnant women should be taken into account in order to characterise the safety for the foetus.

Placental transfer has been seen in pregnant rats, but it is not known whether placental transfer of INTELENCE also occurs in pregnant women. Studies in animals do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development (see section 5.3). Based on animal data the malformative risk is unlikely in humans. The clinical data do not raise safety concern but are very limited.

**Breast-feeding**

It is not known whether etravirine is excreted in human milk. As a general rule, it is recommended that mothers infected by HIV do not breast-feed their babies under any circumstances in order to avoid transmission of HIV.

**Fertility**

No human data on the effect of etravirine on fertility are available. In rats, there was no effect on mating or fertility with etravirine treatment (see section 5.3).

**4.7 Effects on ability to drive and use machines**

INTELENCE has no or negligible influence on the ability to drive and use machines. Adverse drug reactions such as somnolence and vertigo have been reported in INTELENCE treated subjects at incidences similar to placebo (see section 4.8). There is no evidence that INTELENCE may alter the patient’s ability to drive and operate machines, however, the adverse drug reaction profile should be taken into account.

**4.8 Undesirable effects**

**Summary of the safety profile**

The safety assessment is based on all data from 1,203 patients in the Phase III placebo-controlled trials DUET-1 and DUET-2 in antiretroviral treatment-experienced HIV-1 infected adult patients, 599 of whom received INTELENCE (200 mg b.i.d.) (see section 5.1). In these pooled trials, the median exposure for patients in the INTELENCE arm was 52.3 weeks.

The most frequently reported adverse drug reactions (ADRs) (incidence ≥ 10% in the INTELENCE arm) of all intensities occurring in the Phase III studies were rash (19.2% in the INTELENCE arm...
versus 10.9% in the placebo arm), diarrhoea (18.0% in the INTELENCE arm versus 23.5% in the placebo arm), nausea (14.9% in the INTELENCE arm versus 12.7% in the placebo arm) and headache (10.9% in the INTELENCE arm versus 12.7% in the placebo arm). The rates of discontinuation due to any adverse reaction were 7.2% in patients receiving INTELENCE and 5.6% in patients receiving placebo. The most common ADR leading to discontinuation was rash (2.2% in the INTELENCE arm versus 0% in the placebo arm).

Rash was most frequently mild to moderate, generally macular to maculopapular or erythematous, mostly occurred in the second week of therapy, and was infrequent after week 4. Rash was mostly self-limiting, and generally resolved within 1-2 weeks on continued therapy (see section 4.4). The incidence of rash was higher in women compared to men in the INTELENCE arm in the DUET trials (rash ≥ grade 2 was reported in 9/60 [15.0%] women versus 51/539 [9.5%] men; discontinuations due to rash were reported in 3/60 [5.0%] women versus 10/539 [1.9%] men) (see section 4.4). There was no gender difference in severity or treatment discontinuation due to rash. The clinical data are limited and an increased risk of cutaneous reactions in patients with a history of NNRTI-associated cutaneous reaction cannot be excluded (see section 4.4).

Tabulated list of adverse reactions
ADRs of moderate intensity or greater (≥ grade 2) reported in patients treated with INTELENCE are summarised in table 2 (background regimen is indicated as “BR”). Laboratory abnormalities considered ADRs are included in a paragraph below table 2. The ADRs are listed by system organ class (SOC) and frequency. Within each frequency grouping, ADRs are presented in order of decreasing seriousness. Frequencies are defined as very common (≥ 1/10), common (≥ 1/100 to < 1/10) and uncommon (≥ 1/1,000 to < 1/100). Rare and very rare ADRs cannot be detected based on the number of patients included in the DUET trials.

Table 2: DUET-1 and DUET-2 trials

<table>
<thead>
<tr>
<th>System Organ Class (SOC)</th>
<th>Frequency Category</th>
<th>ADRs (INTELENCE + BR versus Placebo + BR)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood and lymphatic system disorders</td>
<td>common</td>
<td>thrombocytopaenia (1.3% vs 1.5%), anaemia (4.0% vs 3.8%)</td>
</tr>
<tr>
<td>Immune system disorders</td>
<td>uncommon</td>
<td>immune reconstitution syndrome (0.2% vs 0.3%), drug hypersensitivity (0.8% vs 1.2%)</td>
</tr>
<tr>
<td>Metabolism and nutrition disorders</td>
<td>common</td>
<td>diabetes mellitus (1.3% vs 0.2%), hyperglycaemia (1.5% vs 0.7%), hypercholesterolaemia (4.3% vs 3.6%), hypertriglyceridaemia (6.3% vs 4.3%), hyperlipidaemia (2.5% vs 1.3%)</td>
</tr>
<tr>
<td></td>
<td>uncommon</td>
<td>anorexia (0.8% vs 1.5%), dyslipidaemia (0.8% vs 0.3%)</td>
</tr>
<tr>
<td>Psychiatric disorders</td>
<td>common</td>
<td>anxiety (1.7% vs 2.6%), insomnia (2.7% vs 2.8%)</td>
</tr>
<tr>
<td></td>
<td>uncommon</td>
<td>confusional state (0.2% vs 0.2%), disorientation (0.2% vs 0.3%), nightmares (0.2% vs 0.2%), sleep disorders (0.5% vs 0.5%), nervousness (0.2% vs 0.3%), abnormal dreams (0.2% vs 0.2%)</td>
</tr>
<tr>
<td>Nervous system disorders</td>
<td>common</td>
<td>peripheral neuropathy (3.8% vs 2.0%), headache (3.0% vs 4.5%)</td>
</tr>
<tr>
<td></td>
<td>uncommon</td>
<td>convulsion (0.5% vs 0.7%), syncope (0.3% vs 0.3%), amnesia (0.3% vs 0.5%), tremor (0.2% vs 0.3%), somnolence (0.7% vs 0.5%), paraesthesia (0.7% vs 0.7%), hypoesthesia (0.5% vs 0.2%), hypersomnia (0.2% vs 0.2%), disturbance in attention (0.2% vs 0.2%)</td>
</tr>
<tr>
<td>Eye disorders</td>
<td>uncommon</td>
<td>blurred vision (0.7% vs 0%)</td>
</tr>
<tr>
<td>Ear and labyrinth disorders</td>
<td>uncommon</td>
<td>vertigo (0.2% vs 0.5%)</td>
</tr>
<tr>
<td>Cardiac disorders</td>
<td>common</td>
<td>myocardial infarction (1.3% vs 0.3%)</td>
</tr>
<tr>
<td></td>
<td>uncommon</td>
<td>atrial fibrillation (0.2% vs 0.2%), angina pectoris (0.5% vs 0.3%)</td>
</tr>
<tr>
<td>Vascular disorders</td>
<td>common</td>
<td>hypertension (3.2% vs 2.5%)</td>
</tr>
<tr>
<td>System</td>
<td>Incidence</td>
<td>Adverse Reactions</td>
</tr>
<tr>
<td>--------------------------------</td>
<td>-----------</td>
<td>----------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Respiratory, thoracic and mediastinal disorders</td>
<td>uncommon</td>
<td>bronchospasm (0.2% vs 0%), exertional dyspnoea (0.5% vs 0.5%)</td>
</tr>
<tr>
<td>Gastrointestinal disorders</td>
<td>common</td>
<td>gastrooesophageal reflux disease (1.8% vs 1.0%), diarrhoea (7.0% vs 11.3%), vomiting (2.8% vs 2.8%), nausea (5.2% vs 4.8%), abdominal pain (3.5% vs 3.1%), flatulence (1.5% vs 1.0%), gastritis (1.5% vs 1.0%)</td>
</tr>
<tr>
<td></td>
<td>uncommon</td>
<td>pancreatitis (0.7% vs 0.3%), haematemesis (0.2% vs 0%), stomatitis (0.2% vs 0.2%), constipation (0.3% vs 0.5%), abdominal distension (0.7% vs 1.0%), dry mouth (0.3% vs 0%), retching (0.2% vs 0%)</td>
</tr>
<tr>
<td>Hepatobiliary disorders</td>
<td>uncommon</td>
<td>hepatitis (0.2% vs 0.3%), hepatic steatosis (0.3% vs 0%), cytolytic hepatitis (0.3% vs 0%), hepatomegaly (0.5% vs 0.2%)</td>
</tr>
<tr>
<td>Skin and subcutaneous tissue disorders</td>
<td>very common</td>
<td>rash (10.0% vs 3.5%)</td>
</tr>
<tr>
<td></td>
<td>common</td>
<td>night sweats (1.0% vs 1.0%)</td>
</tr>
<tr>
<td></td>
<td>uncommon</td>
<td>swelling face (0.3% vs 0%), hyperhidrosis (0.5% vs 0.2%), prurigo (0.7% vs 0.5%), dry skin (0.3% vs 0.2%)</td>
</tr>
<tr>
<td>Renal and urinary disorders</td>
<td>common</td>
<td>renal failure (2.7% vs 2.0%)</td>
</tr>
<tr>
<td>Reproductive system and breast disorders</td>
<td>uncommon</td>
<td>gynaecomastia (0.2% vs 0%)</td>
</tr>
<tr>
<td>General disorders and administration site conditions</td>
<td>common</td>
<td>fatigue (3.5% vs 4.6%)</td>
</tr>
<tr>
<td></td>
<td>uncommon</td>
<td>sluggishness (0.2% vs 0%)</td>
</tr>
</tbody>
</table>

Additional ADRs of at least moderate intensity observed in other trials were angioneurotic oedema, erythema multiforme and haemorrhagic stroke, each reported in no more than 0.5% of patients. Stevens-Johnson Syndrome (rare; < 0.1%) and toxic epidermal necrolysis (very rare; < 0.01%) have been reported during clinical development with INTELENCE.

**Laboratory abnormalities**
Treatment emergent clinical laboratory abnormalities (grade 3 or 4), considered ADRs, reported in ≥ 2% of patients in the INTELENCE arm versus the placebo arm, respectively, were increases in amylase (8.9% vs 9.4%), creatinine (2.0% vs 1.7%), lipase (3.4% vs 2.6%), total cholesterol (8.1% vs 5.3%), low density lipoprotein (LDL) (7.2% vs 6.6%), triglycerides (9.2% vs 5.8%), glucose (3.5% vs 2.4%), alanine aminotransferase (ALT) (3.7% vs 2.0%), aspartate amino transferase (AST) (3.2% vs 2.0%) and decreases in neutrophils (5.0% vs 7.4%) and white blood cell count (2.0% vs 4.3%).

**Description of selected adverse reactions**

**Metabolic parameters**
Weight and levels of blood lipids and glucose may increase during antiretroviral therapy (see section 4.4)

**Immune reconstitution syndrome**
In HIV infected patients with severe immune deficiency at the time of initiation of combination antiretroviral therapy (CART), an inflammatory reaction to asymptomatic or residual opportunistic infections may arise. Autoimmune disorders (such as Graves' disease) have also been reported; however, the reported time to onset is more variable and these events can occur many months after initiation of treatment (see section 4.4).

**Osteonecrosis**
Cases of osteonecrosis have been reported, particularly in patients with generally acknowledged risk factors, advanced HIV disease or long-term exposure to combination antiretroviral therapy. The frequency of this is unknown (see section 4.4).
Paediatric population (6 years to less than 18 years of age)
The safety assessment in children and adolescents is based on the week 48 analysis of the single-arm, Phase II PIANO trial in which 101 antiretroviral treatment-experienced HIV-1 infected paediatric patients, 6 years to less than 18 years of age and weighing at least 16 kg, received INTELENCE in combination with other antiretroviral agents (see section 5.1). The frequency, type and severity of adverse drug reactions in paediatric patients were comparable to those observed in adults. Rash was reported more frequently in female subjects than in male subjects (rash ≥ grade 2 was reported in 13/64 [20.3%] females versus 2/37 [5.4%] males; discontinuations due to rash were reported in 4/64 [6.3%] females versus 0/37 [0%] males) (see section 4.4). Most often, rash was mild to moderate, of macular/papular type, and occurred in the second week of therapy. Rash was mostly self-limiting and generally resolved within 1 week on continued therapy.

Other special populations
Patients co-infected with hepatitis B and/or hepatitis C virus
In the pooled analysis for DUET-1 and DUET-2, the incidence of hepatic events tended to be higher in co-infected subjects treated with INTELENCE compared to co-infected subjects in the placebo group. INTELENCE should be used with caution in these patients (see also sections 4.4 and 5.2).

Adverse drug reactions identified through post marketing experience with INTELENCE
Hypersensitivity reactions, including DRESS, have been reported with INTELENCE. These hypersensitivity reactions were characterised by rash, fever and sometimes organ involvement (including, but not limited to, severe rash or rash accompanied by fever, general malaise, fatigue, muscle or joint aches, blisters, oral lesions, conjunctivitis, hepatitis and eosinophilia) (see section 4.4).

Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.

4.9 Overdose
There are no data with regard to symptomatic overdose with INTELENCE, but it is possible that the most frequent ADRs of INTELENCE, i.e. rash, diarrhoea, nausea, and headache would be the most common symptoms noted. There is no specific antidote for overdose with INTELENCE. Treatment of overdose with INTELENCE consists of general supportive measures including monitoring of vital signs and observation of the clinical status of the patient. Since etravirine is highly protein bound, dialysis is unlikely to result in significant removal of the active substance.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Antivirals for systemic use, non-nucleoside reverse transcriptase inhibitors, ATC code: J05AG04.

Mechanism of action
Etravirine is an NNRTI of human immunodeficiency virus type 1 (HIV-1). Etravirine binds directly to reverse transcriptase (RT) and blocks the RNA-dependent and DNA-dependent DNA polymerase activities by causing a disruption of the enzyme's catalytic site.

Antiviral activity in vitro
Etravirine exhibits activity against wild type HIV-1 in T-cell lines and primary cells with median EC\textsubscript{50} values ranging from 0.9 to 5.5 nM. Etravirine demonstrates activity against HIV-1 group M (subtypes A, B, C, D, E, F, and G) and HIV-1 group O primary isolates with EC\textsubscript{50} values ranging from 0.3 to 1.7 nM and from 11.5 to 21.7 nM, respectively. Although etravirine demonstrates in vitro
activity against wild type HIV-2 with median EC\textsubscript{50} values ranging from 5.7 to 7.2 µM, treatment of HIV-2 infection with etravirine is not recommended in the absence of clinical data. Etravirine retains activity against HIV-1 viral strains resistant to nucleoside reverse transcriptase and/or protease inhibitors. In addition, etravirine demonstrates a fold change (FC) in EC\textsubscript{50} ≤ 3 against 60% of 6,171 NNRTI-resistant clinical isolates.

**Resistance**

Etravirine efficacy in relation to NNRTI resistance at baseline has mainly been analysed with etravirine given in combination with darunavir/ritonavir (DUET-1 and DUET-2). Boosted protease inhibitors, like darunavir/ritonavir, show a higher barrier to resistance compared to other classes of antiretrovirals. The breakpoints for reduced efficacy with etravirine (> 2 etravirine-associated mutations at baseline, see clinical results section) applies when etravirine is given in combination with a boosted protease inhibitor. This breakpoint might be lower in antiretroviral combination therapy not including a boosted protease inhibitor.

In the Phase III trials DUET-1 and DUET-2, mutations that developed most commonly in patients with virologic failure to the INTELENCE containing regimen were V108I, V179F, V179I, Y181C and Y181I, which usually emerged in a background of multiple other NNRTI resistance-associated mutations (RAMs). In all the other trials conducted with INTELENCE in HIV-1 infected patients, the following mutations emerged most commonly: L100I, E138G, V179F, V179I, Y181C and H221Y.

**Cross-resistance**

Following virologic failure of an etravirine-containing regimen it is not recommended to treat patients with efavirenz and/or nevirapine.

**Clinical efficacy and safety**

*Treatment-experienced adult patients*  
*Pivotal studies*

The evidence of efficacy of INTELENCE is based on 48-week data from 2 Phase III trials DUET-1 and DUET-2. These trials were identical in design and similar efficacy for INTELENCE was seen in each trial. The results below are pooled data from the two trials.

**Trial characteristics**

- Design: randomised (1:1), double-blinded, placebo-controlled.
- Treatment: INTELENCE vs. placebo, in addition to a background regimen including darunavir/ritonavir (DRV/rtv), investigator-selected N(t)RTIs and optional enfuvirtide (ENF).
- Main inclusion criteria:
  - HIV-1 plasma viral load > 5,000 HIV-1 RNA copies/ml at screening
  - 1 or more NNRTI resistance-associated mutations (RAMs) at screening or from prior genotypic analysis (i.e., archived resistance)
  - 3 or more primary PI mutations at screening
  - on a stable antiretroviral regimen for at least 8 weeks.
- Stratification: Randomisation was stratified by the intended use of ENF in the BR, previous use of darunavir and screening viral load.
- Virologic response was defined as achieving a confirmed undetectable viral load (< 50 HIV-1 RNA copies/ml).

**Summary of efficacy results**

<table>
<thead>
<tr>
<th>Table 3: DUET-1 and DUET-2 pooled 48-week data</th>
<th>INTELENCE + BR N = 599</th>
<th>Placebo + BR N = 604</th>
<th>Treatment difference (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Baseline characteristics</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median plasma HIV-1 RNA</td>
<td>4.8 log\textsubscript{10} copies/ml</td>
<td>4.8 log\textsubscript{10} copies/ml</td>
<td></td>
</tr>
<tr>
<td>Median CD4 cell count</td>
<td>99 x 10\textsuperscript{6} cells/l</td>
<td>109 x 10\textsuperscript{6} cells/l</td>
<td></td>
</tr>
<tr>
<td><strong>Outcomes</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Confirmed undetectable viral load (< 50 HIV-1 RNA copies/ml)*

<table>
<thead>
<tr>
<th></th>
<th>Overall</th>
<th>De novo ENF</th>
<th>Not de novo ENF</th>
</tr>
</thead>
<tbody>
<tr>
<td>n (%)</td>
<td>363 (60.6%)</td>
<td>109 (71.2%)</td>
<td>254 (57.0%)</td>
</tr>
<tr>
<td></td>
<td>240 (39.7%)</td>
<td>93 (58.5%)</td>
<td>147 (33.0%)</td>
</tr>
</tbody>
</table>

< 400 HIV-1 RNA copies/ml#

<table>
<thead>
<tr>
<th></th>
<th>Overall</th>
<th>De novo ENF</th>
<th>Not de novo ENF</th>
</tr>
</thead>
<tbody>
<tr>
<td>n (%)</td>
<td>428 (71.5%)</td>
<td>109 (71.2%)</td>
<td>254 (57.0%)</td>
</tr>
<tr>
<td></td>
<td>286 (47.4%)</td>
<td>93 (58.5%)</td>
<td>147 (33.0%)</td>
</tr>
</tbody>
</table>

HIV-1 RNA log_{10} mean change from baseline (log_{10} copies/ml)^b

<table>
<thead>
<tr>
<th></th>
<th>Overall</th>
<th>De novo ENF</th>
<th>Not de novo ENF</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>-2.25</td>
<td>-1.49</td>
<td>-0.6</td>
</tr>
</tbody>
</table>

CD4 cell count mean change from baseline (x 10^6/l)^b

<table>
<thead>
<tr>
<th></th>
<th>Overall</th>
<th>De novo ENF</th>
<th>Not de novo ENF</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>+98.2</td>
<td>+72.9</td>
<td>24.4</td>
</tr>
</tbody>
</table>

Any AIDS defining illness and/or death n (%) 35 (5.8%) 59 (9.8%) -3.9%

a Imputations according to the TLOVR algorithm (TLOVR = Time to Loss of Virologic Response).
b Non-completer is failure (NC = F) imputation.
c Treatment differences are based on Least Square Means from an ANCOVA model including the stratification factors.
d Confidence interval around observed difference of response rates; P-value < 0.0001 from logistic regression model, including stratification factors.
e Confidence interval around observed difference of response rates; P-value = 0.0408.
f Confidence interval around observed difference of response rates; P-value from CMH test controlling for stratification factors = 0.0199 for de novo, and < 0.0001 for not de novo.

Since there was a significant interaction effect between treatment and ENF, the primary analysis was done for 2 ENF strata (patients reusing or not using ENF versus patients using ENF de novo). The week 48 results from the pooled analysis of DUET-1 and DUET-2 demonstrated that the INTELENCE arm was superior to the placebo arm irrespective of whether ENF was used de novo (p = 0.0199) or not (p < 0.0001). Results of this analysis (week 48 data) by ENF stratum are shown in table 3.

Significantly fewer patients in the INTELENCE arm reached a clinical endpoint (AIDS-defining illness and/or death) as compared to the placebo arm (p = 0.0408).

A subgroup analysis of the virologic response (defined as a viral load < 50 HIV-1 RNA copies/ml) at week 48 by baseline viral load and baseline CD4 count (pooled DUET data) is presented in table 4.

### Table 4: DUET-1 and DUET-2 pooled data

<table>
<thead>
<tr>
<th>Subgroups</th>
<th>Proportion of subjects with HIV-1 RNA &lt; 50 copies/ml at week 48</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>INTELENCE + BR N = 599</td>
</tr>
<tr>
<td>Baseline HIV-1 RNA</td>
<td></td>
</tr>
<tr>
<td>&lt; 30,000 copies/ml</td>
<td>75.8%</td>
</tr>
<tr>
<td>≥ 30,000 and &lt; 100,000 copies/ml</td>
<td>61.2%</td>
</tr>
<tr>
<td>≥ 100,000 copies/ml</td>
<td>49.1%</td>
</tr>
<tr>
<td>Baseline CD4 count (x 10^6/l)</td>
<td></td>
</tr>
<tr>
<td>&lt; 50</td>
<td>45.1%</td>
</tr>
<tr>
<td>≥ 50 and &lt; 200</td>
<td>65.4%</td>
</tr>
<tr>
<td>≥ 200 and &lt; 350</td>
<td>73.9%</td>
</tr>
<tr>
<td>≥ 350</td>
<td>72.4%</td>
</tr>
</tbody>
</table>

Note: Imputations according to the TLOVR algorithm (TLOVR = Time to Loss of Virologic Response)

Baseline genotype or phenotype and virologic outcome analyses
In DUET-1 and DUET-2, the presence at baseline of 3 or more of the following mutations: V90I, A98G, L100I, K101E, K101P, V106I, V179D, V179F, Y181C, Y181I, Y181V, G190A and G190S, (INTELENCE RAMs) was associated with a decreased virologic response to INTELENCE (see table 5). These individual mutations occurred in the presence of other NNRTI RAMs. V179F was never present without Y181C.

Conclusions regarding the relevance of particular mutations or mutational patterns are subject to change with additional data, and it is recommended to always consult current interpretation systems for analysing resistance test results.

**Table 5:** Proportion of subjects with < 50 HIV-1 RNA copies/ml at week 48 by baseline number of INTELENCE RAMs in the non-viral failure excluded population of pooled DUET-1 and DUET-2 trials

<table>
<thead>
<tr>
<th>Baseline number of INTELENCE RAMs*</th>
<th>Etravirine arms N = 549</th>
<th>Placebo arms N = 569</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Reused/not used ENF</td>
<td>De novo ENF</td>
</tr>
<tr>
<td>All ranges</td>
<td>63.3% (254/401)</td>
<td>78.4% (109/139)</td>
</tr>
<tr>
<td>0</td>
<td>74.1% (117/158)</td>
<td>91.3% (42/46)</td>
</tr>
<tr>
<td>1</td>
<td>61.3% (73/119)</td>
<td>80.4% (41/51)</td>
</tr>
<tr>
<td>2</td>
<td>64.1% (41/64)</td>
<td>66.7% (18/27)</td>
</tr>
<tr>
<td>≥ 3</td>
<td>38.3% (23/60)</td>
<td>53.3% (8/15)</td>
</tr>
</tbody>
</table>

* INTELENCE RAMs = V90I, A98G, L100I, K101E/P, V106I, V179D/F, Y181C/V, G190A/S
Note: all patients in the DUET trials received a background regimen consisting of darunavir/rtv, investigator-selected NRTIs and optional enfuvirtide.

The presence of K103N alone, which was the most prevalent NNRTI mutation in DUET-1 and DUET-2 at baseline, was not identified as a mutation associated with resistance to INTELENCE. Furthermore, the presence of this mutation alone did not affect the response in the INTELENCE arm. Additional data is required to conclude on the influence of K103N when associated with other NNRTIs mutations.

Data from the DUET studies suggest that baseline fold change (FC) in EC$_{50}$ to etravirine was a predictive factor of virologic outcome, with gradually decreasing responses observed above FC 3 and FC 13. FC subgroups are based on the select patient populations in DUET-1 and DUET-2 and are not meant to represent definitive clinical susceptibility breakpoints for INTELENCE.

**Exploratory head to head comparison with protease inhibitor in protease inhibitor naïve patients (trial TMC125-C227)**

TMC125-C227 was an exploratory, randomised, active-controlled open-label trial, which investigated the efficacy and safety of INTELENCE in a treatment regimen, which is not approved under the current indication. In the TMC125-C227 study, INTELENCE (N = 59) was administered with 2 investigator-selected NRTIs (i.e. without a ritonavir-boosted PI) and compared to an investigator-selected combination of a PI with 2 NRTIs (N = 57). The trial population included PI-naïve, NNRTI-experienced patients with evidence of NNRTI resistance.

At week 12, virologic response was greater in the control-PI arm (-2.2 log$_{10}$ copies/ml from baseline; n = 53) compared to the INTELENCE arm (-1.4 log$_{10}$ copies/ml from baseline; n = 40). This difference between treatment arms was statistically significant.

Based on these trial results, INTELENCE is not recommended for use in combination with N(t)RTIs only in patients who have experienced virological failure on an NNRTI- and N(t)RTI-containing regimen.
Paediatric population

Treatment-experienced paediatric patients (6 years to less than 18 years of age)

PIANO is a single-arm, Phase II trial evaluating the pharmacokinetics, safety, tolerability, and efficacy of INTELENCE in 101 antiretroviral treatment-experienced HIV-1 infected paediatric patients 6 years to less than 18 years of age and weighing at least 16 kg. The study enrolled patients on a stable but virologically failing antiretroviral treatment regimen, with a confirmed HIV-1 RNA plasma viral load ≥ 500 copies/ml. Sensitivity of the virus to INTELENCE at screening was required.

The median baseline plasma HIV-1 RNA was 3.9 log_{10} copies/ml, and the median baseline CD4 cell count was 385 x 10^6 cells/l.

Table 6: Virologic responses (ITT - TLOVR), change from baseline in log_{10} viral load (NC = F), and change from baseline in CD4 percentage and cell count (NC = F) at week 24 in the TMC125-C213 and pooled DUET studies

<table>
<thead>
<tr>
<th>Study</th>
<th>Age at screening</th>
<th>Treatment group</th>
<th>TMC125-C213</th>
<th>TMC125-C213</th>
<th>TMC125-C213</th>
<th>Pooled DUET Studies</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>6 to &lt; 12 years</td>
<td>12 to &lt; 18 years</td>
<td>6 to &lt; 18 years</td>
<td>≥ 18 years</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Treatment group</td>
<td>ETR N = 41</td>
<td>ETR N = 60</td>
<td>ETR N = 101</td>
<td>ETR N = 599</td>
</tr>
<tr>
<td>Virologic parameters</td>
<td>Viral load &lt; 50 copies/ml at week 24, n (%)</td>
<td>24 (58.5)</td>
<td>28 (46.7)</td>
<td>52 (51.5)</td>
<td>363 (60.6)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Viral load &lt; 400 copies/ml at week 24, n (%)</td>
<td>28 (68.3)</td>
<td>38 (63.3)</td>
<td>66 (65.3)</td>
<td>445 (74.3)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>≥ 1 log_{10} decrease from baseline at week 24, n (%)</td>
<td>26 (63.4)</td>
<td>38 (63.3)</td>
<td>64 (63.4)</td>
<td>475 (79.3)</td>
<td></td>
</tr>
<tr>
<td>Change from baseline in log_{10} viral load (copies/ml) at week 24, mean (SE) and median (range)</td>
<td>-1.62 (0.21)</td>
<td>-1.44 (0.17)</td>
<td>-1.51 (0.13)</td>
<td>-2.37 (0.05)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>-1.68 (-4.3; 0.9)</td>
<td>-1.68 (-4.0; 0.7)</td>
<td>-1.68 (-4.3; 0.9)</td>
<td>-2.78 (-4.6; 1.4)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Immunologic parameters</td>
<td>Change from baseline in CD4 cell count (x 106 cells/l), mean (SE) and median (range)</td>
<td>125 (33.0)</td>
<td>104 (17.5)</td>
<td>112 (16.9)</td>
<td>83.5 (3.64)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>124 (-410; 718)</td>
<td>81 (-243; 472)</td>
<td>108 (-410; 718)</td>
<td>77.5 (-331; 517)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Change from baseline in CD4 percentage, median (range)</td>
<td>4% (-9; 20)</td>
<td>3% (-4; 14)</td>
<td>4% (-9; 20)</td>
<td>3% (-7; 23)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

N = number of subjects with data; n = number of observations.

At week 48, 53.5% of all paediatric patients had a confirmed undetectable viral load < 50 HIV-1 RNA copies/ml according to the TLOVR algorithm. The proportion of paediatric patients with < 400 HIV-1 RNA copies/ml was 63.4%. The mean change in plasma HIV-1 RNA from baseline to week 48 was -1.53 log_{10} copies/ml, and the mean CD4 cell count increase from baseline was 156 x 10^6 cells/l.

The European Medicines Agency has deferred the obligation to submit the results of studies with INTELENCE in one or more subsets of the paediatric population in human immunodeficiency virus infection, as per Paediatric Investigation Plan (PIP) decision in the granted indication (see section 4.2 for information on paediatric use).

Pregnancy and postpartum

INTELENCE (200 mg b.i.d.), evaluated in combination with other antiretroviral medicinal products in a study of 15 pregnant women during the second and third trimesters of pregnancy and postpartum, demonstrated that exposure to total etravirine was generally higher during pregnancy compared with postpartum, and less so for unbound etravirine exposure (see section 5.2). There were no new clinically relevant safety findings in the mothers or in the newborns in this trial.
5.2 Pharmacokinetic properties

The pharmacokinetic properties of etravirine have been evaluated in adult healthy subjects and in adult and paediatric treatment-experienced HIV-1 infected patients. Exposure to etravirine was lower (35-50%) in HIV-1 infected patients than in healthy subjects.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Etravirine 200 mg b.i.d. N = 575</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>AUC</strong>&lt;sub&gt;12h&lt;/sub&gt; (ng•h/ml)</td>
<td></td>
</tr>
<tr>
<td>Geometric Mean ± Standard Deviation</td>
<td>4,522 ± 4,710</td>
</tr>
<tr>
<td>Median (Range)</td>
<td>4,380 (458 - 59,084)</td>
</tr>
<tr>
<td><strong>C</strong>&lt;sub&gt;0h&lt;/sub&gt; (ng/ml)</td>
<td></td>
</tr>
<tr>
<td>Geometric Mean ± Standard Deviation</td>
<td>297 ± 391</td>
</tr>
<tr>
<td>Median (Range)</td>
<td>298 (2 - 4,852)</td>
</tr>
</tbody>
</table>

* All HIV-1 infected subjects enrolled in Phase III clinical trials received darunavir/ritonavir 600/100 mg b.i.d. as part of their background regimen. Therefore, the pharmacokinetic parameter estimates shown in the table account for reductions in the pharmacokinetic parameters of etravirine due to co-administration of INTELENCE with darunavir/ritonavir.

Note: The median protein binding adjusted EC50 for MT4 cells infected with HIV-1/IIIB in vitro = 4 ng/ml.

Absorption

An intravenous formulation of etravirine is unavailable, thus, the absolute bioavailability of etravirine is unknown. After oral administration with food, the maximum plasma concentration of etravirine is generally achieved within 4 hours.

In healthy subjects, the absorption of etravirine is not affected by co-administration of oral ranitidine or omeprazole, medicinal products that are known to increase gastric pH.

Effect of food on absorption

The systemic exposure (AUC) to etravirine was decreased by about 50% when INTELENCE was administered under fasting conditions, as compared to administration following a meal. Therefore, INTELENCE should be taken following a meal.

Distribution

Etravirine is approximately 99.9% bound to plasma proteins, primarily to albumin (99.6%) and α₁-acid glycoprotein (97.66%-99.02%) *in vitro*. The distribution of etravirine into compartments other than plasma (e.g., cerebrospinal fluid, genital tract secretions) has not been evaluated in humans.

Biotransformation

*In vitro* experiments with human liver microsomes (HLMs) indicate that etravirine primarily undergoes oxidative metabolism by the hepatic cytochrome CYP450 (CYP3A) system and, to a lesser extent, by the CYP2C family, followed by glucuronidation.

Elimination

After administration of a radiolabeled <sup>14</sup>C-etravirine dose, 93.7% and 1.2% of the administered dose of <sup>14</sup>C-etravirine could be retrieved in faeces and urine, respectively. Unchanged etravirine accounted for 81.2% to 86.4% of the administered dose in faeces. Unchanged etravirine in faeces is likely to be unabsorbed drug. Unchanged etravirine was not detected in urine. The terminal elimination half-life of etravirine was approximately 30-40 hours.

Special populations

Paediatric population (6 years to less than 18 years of age)

The pharmacokinetics of etravirine in 101 treatment-experienced HIV-1 infected paediatric patients, 6 years to less than 18 years of age and weighing at least 16 kg, showed that the administered weight-based dosages resulted in etravirine exposure comparable to that in adults receiving INTELENCE 200 mg b.i.d. (see sections 4.2 and 5.2) when administered at a dose corresponding to
5.2 mg/kg b.i.d. The population pharmacokinetic estimates for etravirine AUC$_{12h}$ and C$_{0h}$ are summarised in the table below.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Etravirine N = 101</th>
</tr>
</thead>
<tbody>
<tr>
<td>AUC$_{12h}$ (ng•h/ml)</td>
<td>3,729 ± 4,305</td>
</tr>
<tr>
<td>Geometric Mean ± Standard Deviation</td>
<td></td>
</tr>
<tr>
<td>Median (Range)</td>
<td>4,560 (62 - 28,865)</td>
</tr>
<tr>
<td>C$_{0h}$ (ng/ml)</td>
<td>205 ± 342</td>
</tr>
<tr>
<td>Geometric Mean ± Standard Deviation</td>
<td></td>
</tr>
<tr>
<td>Median (Range)</td>
<td>287 (2 - 2,276)</td>
</tr>
</tbody>
</table>

**Paediatric population (less than 6 years of age)**

The pharmacokinetics of etravirine in paediatric patients less than 6 years of age are under investigation. There are insufficient data at this time to recommend a dose in paediatric patients less than 6 years of age or weighing less than 16 kg (see section 4.2).

**Elderly**

Population pharmacokinetic analysis in HIV infected patients showed that etravirine pharmacokinetics are not considerably different in the age range (18 to 77 years) evaluated, with 6 subjects aged 65 years or older (see sections 4.2 and 4.4).

**Gender**

No significant pharmacokinetic differences have been observed between males and females. A limited number of females were included in the studies.

**Race**

Population pharmacokinetic analysis of etravirine in HIV infected patients indicated no apparent difference in the exposure to etravirine between Caucasian, Hispanic and Black subjects. The pharmacokinetics in other races have not been sufficiently evaluated.

**Hepatic impairment**

Etravirine is primarily metabolised and eliminated by the liver. In a study comparing 8 patients with mild (Child-Pugh Class A) hepatic impairment to 8 matched controls and 8 patients with moderate (Child-Pugh Class B) hepatic impairment to 8 matched controls, the multiple dose pharmacokinetic disposition of etravirine was not altered in patients with mild to moderate hepatic impairment. However, unbound concentrations have not been assessed. Increased unbound exposure could be expected. No dose adjustment is suggested but caution is advised in patients with moderate hepatic impairment. INTELENCE has not been studied in patients with severe hepatic impairment (Child-Pugh Class C) and is therefore not recommended (see sections 4.2 and 4.4).

**Hepatitis B and/or hepatitis C virus co-infection**

Population pharmacokinetic analysis of the DUET-1 and DUET-2 trials showed reduced clearance (potentially leading to increased exposure and alteration of the safety profile) for INTELENCE in HIV-1 infected patients with hepatitis B and/or hepatitis C virus co-infection. In view of the limited data available in hepatitis B and/or C co-infected patients, particular caution should be paid when INTELENCE is used in these patients (see sections 4.4 and 4.8).

**Renal impairment**

The pharmacokinetics of etravirine have not been studied in patients with renal insufficiency. Results from a mass balance study with radioactive $^{14}$C-etravirine showed that < 1.2% of the administered dose of etravirine is excreted in the urine. No unchanged drug was detected in urine so the impact of renal impairment on etravirine elimination is expected to be minimal. As etravirine is highly bound to
plasma proteins, it is unlikely that it will be significantly removed by haemodialysis or peritoneal dialysis (see section 4.2).

**Pregnancy and postpartum**

Study TMC114HIV3015 evaluated etravirine 200 mg b.i.d. in combination with other antiretroviral medicinal products in 15 pregnant women during the second and third trimesters of pregnancy and postpartum. The total etravirine exposure after intake of etravirine 200 mg b.i.d. as part of an antiretroviral regimen was generally higher during pregnancy compared with postpartum (see Table 9). The differences were less pronounced for unbound etravirine exposure. In women receiving etravirine 200 mg b.i.d., higher mean values for C\text{max}, \text{AUC}_{12\text{h}} and C\text{min} were observed during pregnancy compared to postpartum. During the 2\text{nd} and 3\text{rd} trimester of pregnancy mean values of these parameters were comparable.

**Table 9:** Pharmacokinetic results of total etravirine after administration of etravirine 200 mg b.i.d. as part of an antiretroviral regimen, during the 2\text{nd} trimester of pregnancy, the 3\text{rd} trimester of pregnancy, and postpartum.

<table>
<thead>
<tr>
<th>Pharmacokinetics of etravirine</th>
<th>Etravirine 200 mg b.i.d. postpartum N = 10</th>
<th>Etravirine 200 mg b.i.d. 2\text{nd} trimester N = 13</th>
<th>Etravirine 200 mg b.i.d. 3\text{rd} trimester N = 10*</th>
</tr>
</thead>
<tbody>
<tr>
<td>C\text{min}, ng/mL</td>
<td>269 ± 182 (284)</td>
<td>383 ± 210 (346)</td>
<td>349 ± 103 (371)</td>
</tr>
<tr>
<td>C\text{max}, ng/mL</td>
<td>569 ± 261 (528)</td>
<td>774 ± 300 (828)</td>
<td>785 ± 238 (694)</td>
</tr>
<tr>
<td>AUC\text{12h}, h*ng /mL</td>
<td>5004 ± 2521 (5246)</td>
<td>6617 ± 2766 (6836)</td>
<td>6846 ± 1482 (6028)</td>
</tr>
</tbody>
</table>

* n = 9 for AUC\text{12h}

Each subject served as her own control, and with an intra-individual comparison, the total etravirine C\text{min}, C\text{max} and AUC\text{12h} values were 1.2-, 1.4- and 1.4-fold higher, respectively, during the 2\text{nd} trimester of pregnancy as compared to postpartum, and 1.1-, 1.4- and 1.2-fold higher, respectively, based during the 3\text{rd} trimester of pregnancy as compared to postpartum.

**5.3 Preclinical safety data**

Animal toxicology studies have been conducted with etravirine in mice, rats, rabbits and dogs. In mice, the key target organs identified were the liver and the coagulation system. Haemorrhagic cardiomyopathy was only observed in male mice and was considered to be secondary to severe coagulopathy mediated via the vitamin K pathway. In the rat, the key target organs identified were the liver, the thyroid and the coagulation system. Exposure in mice was equivalent to human exposure while in rats it was below the clinical exposure at the recommended dose. In the dog, changes were observed in the liver and gall bladder at exposures approximately 8-fold higher than human exposure observed at the recommended dose (200 mg b.i.d.).

In a study conducted in rats, there were no effects on mating or fertility at exposure levels equivalent to those in humans at the clinically recommended dose. There was no teratogenicity with etravirine in rats and rabbits at exposures equivalent to those observed in humans at the recommended clinical dose. Etravirine had no effect on offspring development during lactation or post weaning at maternal exposures equivalent to those observed at the recommended clinical dose.

Etravirine was not carcinogenic in rats and in male mice. An increase in the incidences of hepatocellular adenomas and carcinomas were observed in female mice. The observed hepatocellular findings in female mice are generally considered to be rodent specific, associated with liver enzyme induction, and of limited relevance to humans. At the highest tested doses, the systemic exposures (based on AUC) to etravirine were 0.6-fold (mice) and between 0.2- and 0.7-fold (rats), relative to those observed in humans at the recommended therapeutic dose (200 mg b.i.d.).

*In vitro* and *in vivo* studies with etravirine revealed no evidence of a mutagenic potential.
6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

INTELENCE 25 mg tablets
- Hypromellose
- Microcrystalline cellulose
- Colloidal anhydrous silica
- Croscarmellose sodium
- Magnesium stearate
- Lactose monohydrate

INTELENCE 100 mg tablets
- Hypromellose
- Microcrystalline cellulose
- Colloidal anhydrous silica
- Croscarmellose sodium
- Magnesium stearate
- Lactose monohydrate

INTELENCE 200 mg tablets
- Hypromellose
- Silicified microcrystalline cellulose
- Microcrystalline cellulose
- Colloidal anhydrous silica
- Croscarmellose sodium
- Magnesium stearate

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

INTELENCE 25 mg tablets
- 2 years if bottle is unopened.
- 8 weeks after opening the bottle.

INTELENCE 100 mg tablets
- 2 years.

INTELENCE 200 mg tablets
- 2 years if bottle is unopened.
- 6 weeks after opening the bottle.

6.4 Special precautions for storage

Store in the original bottle. Keep the bottle tightly closed in order to protect from moisture. Do not remove the desiccant pouches.

6.5 Nature and contents of container

INTELENCE 25 mg tablets
The bottle is a high-density polyethylene (HDPE) plastic bottle containing 120 tablets and 2 desiccant pouches, fitted with a polypropylene (PP) child resistant closure. Each carton contains one bottle.
INTELENCE 100 mg tablets
The bottle is a high-density polyethylene (HDPE) plastic bottle containing 120 tablets and 3 desiccant pouches, fitted with a polypropylene (PP) child resistant closure.
Each carton contains one bottle.

INTELENCE 200 mg tablets
The bottle is a high-density polyethylene (HDPE) plastic bottle containing 60 tablets and 3 desiccant pouches, fitted with a polypropylene (PP) child resistant closure.
Each carton contains one bottle.

6.6 Special precautions for disposal and other handling
Patients who are unable to swallow the tablet(s) whole may disperse the tablet(s) in a glass of water. The patient should be instructed to do the following:
- place the tablet(s) in 5 ml (1 teaspoon) of water, or at least enough liquid to cover the medicine,
- stir well until the water looks milky;
- if desired, add more water or alternatively orange juice or milk (patients should not place the tablets in orange juice or milk without first adding water);
- drink it immediately;
- rinse the glass several times with water, orange juice, or milk and completely swallow the rinse each time to make sure the patient takes the entire dose.

The use of warm (> 40°C) or carbonated beverages should be avoided.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7. MARKETING AUTHORISATION HOLDER

Janssen-Cilag International NV
Turnhoutseweg 30
B-2340 Beerse
Belgium

8. MARKETING AUTHORISATION NUMBER(S)

25 mg: EU/1/08/468/003
100 mg: EU/1/08/468/001
200 mg: EU/1/08/468/002

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 28 August 2008
Date of latest renewal: 28 August 2013

10. DATE OF REVISION OF THE TEXT

Detailed information on this medicine is available on the website of the European Medicines Agency
ANNEX II

A. MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
A. MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE

Name and address of the manufacturer responsible for batch release

Janssen-Cilag SpA
Via C. Janssen
04100 Borgo San Michele
Latina
Italy

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

Medicinal product subject to restricted medical prescription (See Annex I: Summary of Product Characteristics, section 4.2).

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

- Periodic Safety Update Reports

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT

- Risk Management plan (RMP)

The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2. of the Marketing Authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:
- At the request of the European Medicines Agency.
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.
ANNEX III

LABELLING AND PACKAGE LEAFLET
A. LABELLING
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
OUTER CARTON

1. NAME OF THE MEDICINAL PRODUCT

INTELENCE 25 mg tablets
etravirine

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each tablet contains 25 mg etravirine.

3. LIST OF EXCIPIENTS

Contains lactose monohydrate.
See leaflet for further information.

4. PHARMACEUTICAL FORM AND CONTENTS

120 tablets

5. METHOD AND ROUTE OF ADMINISTRATION

Read the package leaflet before use.
Oral use

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

Store in the original bottle. Keep the bottle tightly closed in order to protect from moisture. Do not remove the desiccant pouches.
<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>10.</strong></td>
<td>SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</td>
</tr>
<tr>
<td><strong>11.</strong></td>
<td>NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</td>
</tr>
</tbody>
</table>
|   | Janssen-Cilag International NV  
|   | Turnhoutseweg 30  
|   | B-2340 Beerse  
|   | Belgium |
| **12.**  | MARKETING AUTHORISATION NUMBER |
|   | EU/1/08/468/003 |
| **13.**  | BATCH NUMBER |
|   | Lot |
| **14.**  | GENERAL CLASSIFICATION FOR SUPPLY |
| **15.**  | INSTRUCTIONS ON USE |
| **16.**  | INFORMATION IN BRAILLE |
|   | intelence 25 mg |
| **17.**  | UNIQUE IDENTIFIER – 2D BARCODE |
|   | 2D barcode carrying the unique identifier included. |
| **18.**  | UNIQUE IDENTIFIER - HUMAN READABLE DATA |
|   | PC:  
|   | SN:  
<p>|   | NN: |</p>
<table>
<thead>
<tr>
<th>PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING</th>
</tr>
</thead>
<tbody>
<tr>
<td>BOTTLE LABEL</td>
</tr>
</tbody>
</table>

1. **NAME OF THE MEDICINAL PRODUCT**

INTELENCE 25 mg tablets
etravirine

2. **STATEMENT OF ACTIVE SUBSTANCE(S)**

Each tablet contains 25 mg etravirine.

3. **LIST OF EXCIPIENTS**

Contains lactose monohydrate.

4. **PHARMACEUTICAL FORM AND CONTENTS**

120 tablets

5. **METHOD AND ROUTE OF ADMINISTRATION**

Read the package leaflet before use.
Oral use

6. **SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN**

Keep out of the sight and reach of children.

7. **OTHER SPECIAL WARNING(S), IF NECESSARY**

8. **EXPIRY DATE**

EXP

9. **SPECIAL STORAGE CONDITIONS**

Store in the original bottle. Keep the bottle tightly closed in order to protect from moisture.
10. **SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

11. **NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

   Janssen-Cilag International NV  
   Turnhoutseweg 30  
   B-2340 Beerse  
   Belgium

12. **MARKETING AUTHORISATION NUMBER**

   EU/1/08/468/003

13. **BATCH NUMBER**

   Lot

14. **GENERAL CLASSIFICATION FOR SUPPLY**

15. **INSTRUCTIONS ON USE**

16. **INFORMATION IN BRAILLE**
<table>
<thead>
<tr>
<th>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</th>
</tr>
</thead>
<tbody>
<tr>
<td>OUTER CARTON</td>
</tr>
</tbody>
</table>

1. **NAME OF THE MEDICINAL PRODUCT**

INTELENCE 100 mg tablets  
eetravirine

2. **STATEMENT OF ACTIVE SUBSTANCE(S)**

Each tablet contains 100 mg eetravirine.

3. **LIST OF EXCIPIENTS**

Contains lactose monohydrate.  
See leaflet for further information.

4. **PHARMACEUTICAL FORM AND CONTENTS**

120 tablets

5. **METHOD AND ROUTE OF ADMINISTRATION**

Read the package leaflet before use.  
Oral use

6. **SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN**

Keep out of the sight and reach of children.

7. **OTHER SPECIAL WARNING(S), IF NECESSARY**

8. **EXPIRY DATE**

EXP

9. **SPECIAL STORAGE CONDITIONS**

Store in the original bottle. Keep the bottle tightly closed in order to protect from moisture. Do not remove the desiccant pouches.
10. **SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

11. **NAME AND ADDRESS OF THE MARKETING AUTHORIZATION HOLDER**

   Janssen-Cilag International NV  
   Turnhoutseweg 30  
   B-2340 Beerse  
   Belgium

12. **MARKETING AUTHORIZATION NUMBER**

   EU/1/08/468/001

13. **BATCH NUMBER**

   Lot

14. **GENERAL CLASSIFICATION FOR SUPPLY**

15. **INSTRUCTIONS ON USE**

16. **INFORMATION IN BRAILLE**

   intelence 100 mg

17. **UNIQUE IDENTIFIER – 2D BARCODE**

   2D barcode carrying the unique identifier included.

18. **UNIQUE IDENTIFIER - HUMAN READABLE DATA**

   PC:  
   SN:  
   NN:
PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING
BOTTLE LABEL

1. NAME OF THE MEDICINAL PRODUCT

INTELENCE 100 mg tablets
etravirine

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each tablet contains 100 mg etravirine.

3. LIST OF EXCIPIENTS

Contains lactose monohydrate.

4. PHARMACEUTICAL FORM AND CONTENTS

120 tablets

5. METHOD AND ROUTE OF ADMINISTRATION

Read the package leaflet before use.
Oral use

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

Store in the original bottle. Keep the bottle tightly closed in order to protect from moisture.
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Janssen-Cilag International NV
Turnhoutseweg 30
B-2340 Beerse
Belgium

12. MARKETING AUTHORISATION NUMBER

EU/1/08/468/001

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE
PARTICULARS TO APPEAR ON THE OUTER PACKAGING

OUTER CARTON

1. NAME OF THE MEDICINAL PRODUCT

INTELENCE 200 mg tablets
etravirine

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each tablet contains 200 mg etravirine.

3. LIST OF EXCIPIENTS

4. PHARMACEUTICAL FORM AND CONTENTS

60 tablets

5. METHOD AND ROUTE OF ADMINISTRATION

Read the package leaflet before use.
Oral use

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

Store in the original bottle. Keep the bottle tightly closed in order to protect from moisture. Do not remove the desiccant pouches.
10. **SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

11. **NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Janssen-Cilag International NV
Turnhoutseweg 30
B-2340 Beerse
Belgium

12. **MARKETING AUTHORISATION NUMBER**

EU/1/08/468/002

13. **BATCH NUMBER**

Lot

14. **GENERAL CLASSIFICATION FOR SUPPLY**

15. **INSTRUCTIONS ON USE**

16. **INFORMATION IN BRAILLE**

intelence 200 mg

17. **UNIQUE IDENTIFIER – 2D BARCODE**

2D barcode carrying the unique identifier included.

18. **UNIQUE IDENTIFIER - HUMAN READABLE DATA**

PC:
SN:
NN:
PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING
BOTTLE LABEL

1. NAME OF THE MEDICINAL PRODUCT

INTELENCE 200 mg tablets
etravirine

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each tablet contains 200 mg etravirine.

3. LIST OF EXCIPIENTS

4. PHARMACEUTICAL FORM AND CONTENTS

60 tablets

5. METHOD AND ROUTE OF ADMINISTRATION

Read the package leaflet before use.
Oral use

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

Store in the original bottle. Keep the bottle tightly closed in order to protect from moisture.
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Janssen-Cilag International NV
Turnhoutseweg 30
B-2340 Beerse
Belgium

12. MARKETING AUTHORISATION NUMBER

EU/1/08/468/002

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE
B. PACKAGE LEAFLET
INTELENCE 25 mg tablets
etravirine

What is INTELENCE and what it is used for

INTELENCE contains the active substance etravirine. INTELENCE belongs to a group of anti-HIV medicines called non-nucleoside reverse transcriptase inhibitors (NNRTIs).

INTELENCE is a medicine used for the treatment of Human Immunodeficiency Virus (HIV) infection. INTELENCE works by reducing the amount of HIV in your body. This will improve your immune system and reduces the risk of developing illnesses linked to HIV infection.

INTELENCE is used in combination with other anti-HIV medicines to treat adults and children 6 years of age and older who are infected by HIV and who have used other anti-HIV medicines before.

Your doctor will discuss with you which combination of medicines is best for you.

What you need to know before you take INTELENCE

Do not take INTELENCE

- if you are allergic to etravirine or any of the other ingredients of this medicine (listed in section 6)
- if you are taking elbasvir/grazoprevir (a medicine to treat hepatitis C infection).

Warnings and precautions

Talk to your doctor or pharmacist before taking INTELENCE.

INTELENCE is not a cure for HIV infection. It is part of a treatment reducing the amount of virus in the blood. You can still pass on HIV when taking this medicine, although the risk is lowered by effective antiretroviral therapy. Discuss with your physician the precautions needed to avoid infecting other people.

People taking INTELENCE may still develop infections or other illnesses associated with HIV infection. You must keep in regular contact with your doctor.
Older people
INTELENCE has only been used in a limited number of patients of 65 years or older. If you belong to this age group, please discuss the use of INTELENCE with your doctor.

Bone problems
Some patients taking combination antiretroviral therapy may develop a bone disease called osteonecrosis (death of bone tissue caused by loss of blood supply to the bone). The length of combination antiretroviral therapy, corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index, among others, may be some of the many risk factors for developing this disease. Signs of osteonecrosis are joint stiffness, aches and pains (especially of the hip, knee and shoulder) and difficulty in movement. If you notice any of these symptoms please inform your doctor.

Tell your doctor about your situation
Make sure that you check the following points and tell your doctor if any of these apply to you.
- Tell your doctor if you develop a rash. If a rash occurs, it usually appears soon after anti-HIV treatment with INTELENCE is started and often disappears within 1 to 2 weeks, even with continued use of the medicine. Occasionally, during INTELENCE treatment, you can experience hypersensitivity reaction (allergic reaction including rash and fever but also swelling of the face, tongue or throat, difficulty in breathing or swallowing) which could be potentially life-threatening. Please contact your doctor immediately if you get a hypersensitivity reaction. Your doctor will advise you how to deal with your symptoms and whether INTELENCE must be stopped. If you have stopped treatment due to a hypersensitivity reaction, you should not restart therapy with INTELENCE.
- Tell your doctor if you have or have had problems with your liver, including hepatitis B and/or C. Your doctor may evaluate how severe your liver disease is before deciding if you can take INTELENCE.
- Tell your doctor immediately if you notice any symptoms of infections. In some patients with advanced HIV infection and a history of opportunistic infection, signs and symptoms of inflammation from previous infections may occur soon after anti-HIV treatment is started. It is believed that these symptoms are due to an improvement in the body’s immune response, enabling the body to fight infections that may have been present with no obvious symptoms.
- In addition to the opportunistic infections, autoimmune disorders (a condition that occurs when the immune system attacks healthy body tissue) may also occur after you start taking medicines for the treatment of your HIV infection. Autoimmune disorders may occur many months after the start of treatment. If you notice any symptoms of infection or other symptoms such as muscle weakness, weakness beginning in the hands and feet and moving up towards the trunk of the body, palpitations, tremor or hyperactivity, please inform your doctor immediately to seek necessary treatment.

Children and adolescents
Do not give this medicine to children less than 6 years of age or weighing less than 16 kg because the potential benefits and risks have not yet been established.

Other medicines and INTELENCE
INTELENCE might interact with other medicines. Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.

In most cases, INTELENCE can be combined with anti-HIV medicines belonging to another class. However, some combinations are not recommended. In other cases, increased monitoring and/or a change in the dose of the medicine may be needed. Therefore, always tell your doctor which other anti-HIV medicines you take. Furthermore, it is important that you carefully read the package leaflets that are provided with these medicines. Follow your doctor’s instruction carefully on which medicines can be combined.
It is not recommended to combine INTELENCE with any of the following medicines:
- tipranavir/ritonavir, efavirenz, nevirapine, rilpivirine, indinavir, nelfinavir, atazanavir/cobicistat, darunavir/cobicistat (anti-HIV medicine)
- carbamazepine, phenobarbital, phenytoin (medicines to prevent seizures)
- rifampicin, because it is contraindicated with boosted protease inhibitors, and rifapentine (medicines to treat some infections such as tuberculosis)
- products that contain St John’s wort (Hypericum perforatum) (a herbal product used for depression)
- daclatasvir, simeprevir (medicines to treat hepatitis C infection).

If you are taking any of these, ask your doctor for advice.

The effects of INTELENCE or other medicines might be influenced if you take INTELENCE together with any of the following medicines. Tell your doctor if you take:
- amiodarone, bepridil, digoxin, disopyramide, flecainide, lidocaine, mexiletine, propafenone and quinidine (medicines to treat certain heart disorders, e.g., abnormal heart beat)
- warfarin (a medicine used to reduce clotting of the blood). Your doctor will have to check your blood
- fluconazole, itraconazole, ketoconazole, posaconazole, voriconazole (medicines to treat fungal infections)
- clarithromycin, rifabutin (antibiotics)
- artemether/lumefantrine (a medicine to treat malaria)
- diazepam (medicines to treat trouble with sleeping and/or anxiety)
- dexamethasone (a corticosteroid used in a variety of conditions such as inflammation and allergic reactions)
- boceprevir (a medicine to treat hepatitis C infection)
- atorvastatin, fluvastatin, lovastatin, rosuvastatin, simvastatin (cholesterol-lowering medicines)
- cyclosporine, sirolimus, tacrolimus (immunosuppressants)
- sildenafil, vardenafil, tadalafil (medicines to treat erectile dysfunction and/or pulmonary arterial hypertension)
- clopidogrel (a medicine to prevent blood clots).

Pregnancy and breast-feeding
Tell your doctor immediately if you are pregnant. Pregnant women should not take INTELENCE unless specifically directed by the doctor.
HIV infected mothers must not breast-feed, as there is a possibility of infecting the baby with HIV.

Driving and using machines
Do not drive or operate machines if you feel sleepy or dizzy after taking your medicines.

INTELENCE contains lactose
INTELENCE tablets contain lactose. If you have been told by your doctor that you have an intolerance to some sugars (lactose), contact your doctor before taking this medicine.

3. How to take INTELENCE
Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.

Use in adults
The recommended dose of INTELENCE is two tablets twice a day.
In the morning, take two 100 milligram INTELENCE tablets, following a meal.
In the evening, take two 100 milligram INTELENCE tablets, following a meal.

Use in children and adolescents 6 years of age and older and weighing at least 16 kg
The doctor will work out the right dose based on the weight of the child.
The doctor will inform you exactly how much INTELENCE the child should take.

Do not stop administering INTELENCE without talking to the child’s doctor.

The other HIV medicines used in combination with INTELENCE should be taken by the child as recommended by the child’s doctor.

**Instructions for taking INTELENCE for all patients**

It is important that you take INTELENCE following a meal. If you take INTELENCE on an empty stomach, only half the amount of INTELENCE is absorbed. Follow your doctor’s advice on the type of meal you should be taking with INTELENCE.

Swallow the INTELENCE tablet(s) whole with a glass of water. Do not chew the tablet(s). The tablet can be divided into equal doses.

- If you are unable to swallow the INTELENCE tablet(s) whole, you may do the following:
  - place the tablet(s) in 5 ml (1 teaspoon) of water, or at least enough liquid to cover the medicine,
  - stir well until the water looks milky,
  - if desired, add more water or alternatively orange juice or milk (do not place the tablets in orange juice or milk without first adding water),
  - drink it immediately,
  - rinse the glass several times with water, orange juice, or milk and completely swallow the rinse each time to make sure you take the entire dose.
- Do not use warm (> 40°C) or carbonated beverages when taking INTELENCE tablet(s).

**Removing the child resistant cap**

The plastic bottle comes with a child resistant cap and should be opened as follows:

- Push the plastic screw cap down while turning it counter clockwise.
- Remove the unscrewed cap.

**If you take more INTELENCE than you should**

Contact your doctor or pharmacist immediately. The most frequent side effects of INTELENCE are rash, diarrhoea, nausea, and headache (see section ‘4. Possible side effects’).

**If you forget to take INTELENCE**

If you notice **within 6 hours of the time you usually take INTELENCE**, you must take the tablet(s) as soon as possible. Always take the tablet(s) following a meal. Then take the next dose as usual. If you notice **after 6 hours**, then skip the intake and take the next doses as usual. Do not take a double dose to make up for a forgotten dose.

**Do not stop taking INTELENCE without talking to your doctor first**

HIV therapy may increase your sense of well-being. Even if you feel better, do not stop taking INTELENCE or your other anti-HIV medicines. Doing so could increase the risk of the virus developing resistance. Talk to your doctor first.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

**4. Possible side effects**

During HIV therapy there may be an increase in weight and in levels of blood lipids and glucose. This is partly linked to restored health and life style, and in the case of blood lipids sometimes to the HIV medicines themselves. Your doctor will test for these changes.
Like all medicines, this medicine can cause side effects, although not everybody gets them.

The frequency rate of the side effects associated with INTELENCE is given below.

Very common side effects (may affect more than 1 in 10 people)
- skin rash. The rash is usually mild to moderate. In rare instances, very serious rash has been reported which can be potentially life-threatening. It is therefore important to contact your doctor immediately if you develop a rash. Your doctor will advise you how to deal with your symptoms and whether INTELENCE must be stopped.

Common side effects (may affect up to 1 in 10 people)
- headache, tingling or pain in hands or feet, numbness, tiredness, sleeplessness, anxiety;
- diarrhoea, nausea, vomiting, heartburn, abdominal pain, inflammation of the stomach, flatulence;
- kidney failure, high blood pressure, heart attack, diabetes;
- night sweats.

Uncommon side effects (may affect up to 1 in 100 people)
- angina, irregular heart rhythm;
- loss of skin sensibility, drowsiness, trembling, fainting, sleepiness, loss of memory, seizures, stroke, disturbance in attention;
- blurred vision, dizziness, sluggishness;
- difficulty breathing;
- dry mouth, mouth inflammation, retching, constipation, distension of the abdomen, inflammation of the pancreas, vomiting blood, decrease of appetite;
- excessive sweating, itching, dry skin, swelling of the face and/or throat;
- allergic reactions (hypersensitivity), symptoms of infection (for example enlarged lymph nodes and fever);
- liver problems such as hepatitis;
- swelling of breasts in men;
- sleep disorders, abnormal dreams, confusion, disorientation, nervousness;

Not known (frequency cannot be estimated from the available data)
- severe hypersensitivity reactions characterised by rash accompanied by fever and organ inflammation such as hepatitis.

**Reporting of side effects**
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.

5. **How to store INTELENCE**

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and on the bottle after EXP. The expiry date refers to the last day of that month.

INTELENCE tablets should be stored in the original bottle. Keep the bottle tightly closed in order to protect from moisture. The bottle contains 2 little pouches (desiccants) to keep the tablets dry. These pouches should stay in the bottle all the time and are not to be eaten.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
6. Contents of the pack and other information

What INTELENCE contains
- The active substance is etravirine. Each tablet of INTELENCE contains 25 mg of etravirine.
- The other ingredients are hypromellose, microcrystalline cellulose, colloidal anhydrous silica, croscarmellose sodium, magnesium stearate and lactose (as monohydrate).

What INTELENCE looks like and contents of the pack
This medicinal product is presented as white to off-white, oval, scored tablet, with “TMC” on one side. The tablet can be divided into two equal doses.
A plastic bottle containing 120 tablets and 2 pouches to keep the tablets dry.

Marketing Authorisation Holder
Janssen-Cilag International NV, Turnhoutseweg 30, B-2340 Beerse, Belgium

Manufacturer
Janssen-Cilag SpA, Via C. Janssen, 04100 Borgo San Michele, Latina, Italy

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

België/Belgique/Belgien
Janssen-Cilag NV
Antwerpseweg 15-17
B-2340 Beerse
Tel/Tél: +32 14 64 94 11

Lietuva
UAB "JOHNSON & JOHNSON"
Geležinio Vilko g. 18A
LT-08104 Vilnius
Tel: +370 5 278 68 88

България
„Джонсън & Джонсън България” ЕООД
ж.к. Младост 4
Бизнес Парк София, сграда 4
София 1766
Tel.: +359 2 489 94 00

Luxembourg/Luxemburg
Janssen-Cilag NV
Antwerpseweg 15-17
B-2340 Beerse
Belgique/Belgien
Tel/Tél: +32 14 64 94 11

Česká republika
Janssen-Cilag s.r.o.
Karla Engliše 3201/06
CZ-150 00 Praha 5 - Smíchov
Tel: +420 227 012 227

Magyarország
Janssen-Cilag Kft.
Nagyenyed u. 8-14
H-Budapest, 1123
Tel.: +36 1 884 2858

Danmark
Janssen-Cilag A/S
Bregnerødvej 133
DK-3460 Birkerød
Tlf: +45 45 94 82 82

Malta
AM MANGION LTD.
Mangion Building, Triq Ġdida fi Triq Valletta
MT-Hal-Luqa LQA 6000
Tel: +356 2397 6000

Deutschland
Janssen-Cilag GmbH
Johnson & Johnson Platz 1
D-41470 Neuss
Tel: +49 2137 955-955

Nederland
Janssen-Cilag B.V.
Graaf Engelbertlaan 75
NL-4837 DS Breda
Tel: +31 76 711 1111
This leaflet was last revised in {MM/YYYY}.

Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu/.
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or pharmacist.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet
1. What INTELENCE is and what it is used for
2. What you need to know before you take INTELENCE
3. How to take INTELENCE
4. Possible side effects
5. How to store INTELENCE
6. Contents of the pack and other information

1. What INTELENCE is and what it is used for

INTELENCE contains the active substance etravirine. INTELENCE belongs to a group of anti-HIV medicines called non-nucleoside reverse transcriptase inhibitors (NNRTIs).

INTELENCE is a medicine used for the treatment of Human Immunodeficiency Virus (HIV) infection. INTELENCE works by reducing the amount of HIV in your body. This will improve your immune system and reduces the risk of developing illnesses linked to HIV infection.

INTELENCE is used in combination with other anti-HIV medicines to treat adults and children 6 years of age and older who are infected by HIV and who have used other anti-HIV medicines before.

Your doctor will discuss with you which combination of medicines is best for you.

2. What you need to know before you take INTELENCE

Do not take INTELENCE
- if you are allergic to etravirine or any of the other ingredients of this medicine (listed in section 6)
- if you are taking elbasvir/grazoprevir (a medicine to treat hepatitis C infection).

Warnings and precautions
Talk to your doctor or pharmacist before taking INTELENCE.

INTELENCE is not a cure for HIV infection. It is part of a treatment reducing the amount of virus in the blood. You can still pass on HIV when taking this medicine, although the risk is lowered by effective antiretroviral therapy. Discuss with your physician the precautions needed to avoid infecting other people.

People taking INTELENCE may still develop infections or other illnesses associated with HIV infection. You must keep in regular contact with your doctor.
Older people
INTELENCE has only been used in a limited number of patients of 65 years or older. If you belong to this age group, please discuss the use of INTELENCE with your doctor.

Bone problems
Some patients taking combination antiretroviral therapy may develop a bone disease called osteonecrosis (death of bone tissue caused by loss of blood supply to the bone). The length of combination antiretroviral therapy, corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index, among others, may be some of the many risk factors for developing this disease. Signs of osteonecrosis are joint stiffness, aches and pains (especially of the hip, knee and shoulder) and difficulty in movement. If you notice any of these symptoms please inform your doctor.

Tell your doctor about your situation
Make sure that you check the following points and tell your doctor if any of these apply to you.

- Tell your doctor if you develop a rash. If a rash occurs, it usually appears soon after anti-HIV treatment with INTELENCE is started and often disappears within 1 to 2 weeks, even with continued use of the medicine. Occasionally, during INTELENCE treatment, you can experience hypersensitivity reaction (allergic reaction including rash and fever but also swelling of the face, tongue or throat, difficulty in breathing or swallowing) which could be potentially life-threatening. Please contact your doctor immediately if you get a hypersensitivity reaction. Your doctor will advise you how to deal with your symptoms and whether INTELENCE must be stopped. If you have stopped treatment due to a hypersensitivity reaction, you should not restart therapy with INTELENCE.

- Tell your doctor if you have or have had problems with your liver, including hepatitis B and/or C. Your doctor may evaluate how severe your liver disease is before deciding if you can take INTELENCE.

- Tell your doctor immediately if you notice any symptoms of infections. In some patients with advanced HIV infection and a history of opportunistic infection, signs and symptoms of inflammation from previous infections may occur soon after anti-HIV treatment is started. It is believed that these symptoms are due to an improvement in the body’s immune response, enabling the body to fight infections that may have been present with no obvious symptoms.

- In addition to the opportunistic infections, autoimmune disorders (a condition that occurs when the immune system attacks healthy body tissue) may also occur after you start taking medicines for the treatment of your HIV infection. Autoimmune disorders may occur many months after the start of treatment. If you notice any symptoms of infection or other symptoms such as muscle weakness, weakness beginning in the hands and feet and moving up towards the trunk of the body, palpitations, tremor or hyperactivity, please inform your doctor immediately to seek necessary treatment.

Children and adolescents
Do not give this medicine to children less than 6 years of age or weighing less than 16 kg because the potential benefits and risks have not yet been established.

Other medicines and INTELENCE
INTELENCE might interact with other medicines. Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.

In most cases, INTELENCE can be combined with anti-HIV medicines belonging to another class. However, some combinations are not recommended. In other cases, increased monitoring and/or a change in the dose of the medicine may be needed. Therefore, always tell your doctor which other anti-HIV medicines you take. Furthermore, it is important that you carefully read the package leaflets that are provided with these medicines. Follow your doctor’s instruction carefully on which medicines can be combined.
It is not recommended to combine INTELENCE with any of the following medicines:
- tipranavir/ritonavir, efavirenz, nevirapine, rilpivirine, indinavir, nelfinavir, atazanavir/cobicistat, darunavir/cobicistat (anti-HIV medicine)
- carbamazepine, phenobarbital, phenytoin (medicines to prevent seizures)
- rifampicin, because it is contraindicated with boosted protease inhibitors, and rifapentine (medicines to treat some infections such as tuberculosis)
- products that contain St John’s wort (Hypericum perforatum) (a herbal product used for depression)
- daclatasvir, simeprevir (medicines to treat hepatitis C infection).

If you are taking any of these, ask your doctor for advice.

The effects of INTELENCE or other medicines might be influenced if you take INTELENCE together with any of the following medicines. Tell your doctor if you take:
- amiodarone, bepridil, digoxin, disopyramide, flecaainide, lidocaine, mexiletine, propafenone and quinidine (medicines to treat certain heart disorders, e.g., abnormal heart beat)
- warfarin (a medicine used to reduce clotting of the blood). Your doctor will have to check your blood
- fluconazole, itraconazole, ketoconazole, posaconazole, voriconazole (medicines to treat fungal infections)
- clarithromycin, rifabutin (antibiotics)
- artemether/lumefantrine (a medicine to treat malaria)
- diazepam (medicines to treat trouble with sleeping and/or anxiety)
- dexamethasone (a corticosteroid used in a variety of conditions such as inflammation and allergic reactions)
- boceprevir (a medicine to treat hepatitis C infection)
- atorvastatin, fluvastatin, lovastatin, rosuvastatin, simvastatin (cholesterol-lowering medicines)
- cyclosporine, sirolimus, tacrolimus (immunosuppressants)
- sildenafil, vardenafil, tadalafil (medicines to treat erectile dysfunction and/or pulmonary arterial hypertension)
- clopidogrel (a medicine to prevent blood clots).

Pregnancy and breast-feeding
Tell your doctor immediately if you are pregnant. Pregnant women should not take INTELENCE unless specifically directed by the doctor.
HIV infected mothers must not breast-feed, as there is a possibility of infecting the baby with HIV.

Driving and using machines
Do not drive or operate machines if you feel sleepy or dizzy after taking your medicines.

INTELENCE contains lactose
INTELENCE tablets contain lactose. If you have been told by your doctor that you have an intolerance to some sugars (lactose), contact your doctor before taking this medicine.

3. How to take INTELENCE
Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.

Use in adults
The recommended dose of INTELENCE is two tablets twice a day.
In the morning, take two 100 milligram INTELENCE tablets, following a meal.
In the evening, take two 100 milligram INTELENCE tablets, following a meal.

Use in children and adolescents 6 years of age and older and weighing at least 16 kg
The doctor will work out the right dose based on the weight of the child.
The doctor will inform you exactly how much INTELENCE the child should take.

Do not stop administering INTELENCE without talking to the child’s doctor.

The other HIV medicines used in combination with INTELENCE should be taken by the child as recommended by the child’s doctor.

**Instructions for taking INTELENCE for all patients**

It is important that you take INTELENCE following a meal. If you take INTELENCE on an empty stomach, only half the amount of INTELENCE is absorbed. Follow your doctor’s advice on the type of meal you should be taking with INTELENCE.

Swallow the INTELENCE tablet(s) whole with a glass of water. Do not chew the tablet(s).

- If you are unable to swallow the INTELENCE tablet(s) whole, you may do the following:
  - place the tablet(s) in 5 ml (1 teaspoon) of water, or at least enough liquid to cover the medicine,
  - stir well until the water looks milky,
  - if desired, add more water or alternatively orange juice or milk (do not place the tablets in orange juice or milk without first adding water),
  - drink it immediately,
  - rinse the glass several times with water, orange juice, or milk and completely swallow the rinse each time to make sure you take the entire dose.
- Do not use warm (> 40°C) or carbonated beverages when taking INTELENCE tablet(s).

**Removing the child resistant cap**

The plastic bottle comes with a child resistant cap and should be opened as follows:

- Push the plastic screw cap down while turning it counter clockwise.
- Remove the unscrewed cap.

**If you take more INTELENCE than you should**

Contact your doctor or pharmacist immediately. The most frequent side effects of INTELENCE are rash, diarrhoea, nausea, and headache (see section ‘4. Possible side effects’).

**If you forget to take INTELENCE**

If you notice within 6 hours of the time you usually take INTELENCE, you must take the tablet(s) as soon as possible. Always take the tablet(s) following a meal. Then take the next dose as usual. If you notice after 6 hours, then skip the intake and take the next doses as usual. Do not take a double dose to make up for a forgotten dose.

**Do not stop taking INTELENCE without talking to your doctor first**

HIV therapy may increase your sense of well-being. Even if you feel better, do not stop taking INTELENCE or your other anti-HIV medicines. Doing so could increase the risk of the virus developing resistance. Talk to your doctor first.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

**4. Possible side effects**

During HIV therapy there may be an increase in weight and in levels of blood lipids and glucose. This is partly linked to restored health and life style, and in the case of blood lipids sometimes to the HIV medicines themselves. Your doctor will test for these changes.

Like all medicines, this medicine can cause side effects, although not everybody gets them.
The frequency rate of the side effects associated with INTELENCE is given below.

Very common side effects (may affect more than 1 in 10 people)
- skin rash. The rash is usually mild to moderate. In rare instances, very serious rash has been reported which can be potentially life-threatening. It is therefore important to contact your doctor immediately if you develop a rash. Your doctor will advise you how to deal with your symptoms and whether INTELENCE must be stopped.

Common side effects (may affect up to 1 in 10 people)
- headache, tingling or pain in hands or feet, numbness, tiredness, sleeplessness, anxiety;
- diarrhoea, nausea, vomiting, heartburn, abdominal pain, inflammation of the stomach, flatulence;
- kidney failure, high blood pressure, heart attack, diabetes;
- night sweats.

Uncommon side effects (may affect up to 1 in 100 people)
- angina, irregular heart rhythm;
- loss of skin sensibility, drowsiness, trembling, fainting, sleepiness, loss of memory, seizures, stroke, disturbance in attention;
- blurred vision, dizziness, sluggishness;
- difficulty breathing;
- dry mouth, mouth inflammation, retching, constipation, distension of the abdomen, inflammation of the pancreas, vomiting blood, decrease of appetite;
- excessive sweating, itching, dry skin, swelling of the face and/or throat;
- allergic reactions (hypersensitivity), symptoms of infection (for example enlarged lymph nodes and fever);
- liver problems such as hepatitis;
- swelling of breasts in men;
- sleep disorders, abnormal dreams, confusion, disorientation, nervousness;

Not known (frequency cannot be estimated from the available data)
- severe hypersensitivity reactions characterised by rash accompanied by fever and organ inflammation such as hepatitis.

Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store INTELENCE

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and on the bottle after EXP. The expiry date refers to the last day of that month.

INTELENCE tablets should be stored in the original bottle. Keep the bottle tightly closed in order to protect from moisture. The bottle contains 3 little pouches (desiccants) to keep the tablets dry. These pouches should stay in the bottle all the time and are not to be eaten.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
6. Contents of the pack and other information

What INTELENCE contains
- The active substance is etravirine. Each tablet of INTELENCE contains 100 mg of etravirine.
- The other ingredients are hypromellose, microcrystalline cellulose, colloidal anhydrous silica, croscarmellose sodium, magnesium stearate and lactose (as monohydrate).

What INTELENCE looks like and contents of the pack
This medicinal product is presented as white to off-white, oval tablet, with “T125” on one side and “100” on the other side.
A plastic bottle containing 120 tablets and 3 pouches to keep the tablets dry.

Marketing Authorisation Holder
Janssen-Cilag International NV, Turnhoutseweg 30, B-2340 Beerse, Belgium

Manufacturer
Janssen-Cilag SpA, Via C. Janssen, 04100 Borgo San Michele, Latina, Italy

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

<table>
<thead>
<tr>
<th>België/Belgique/Belgien</th>
<th>Lietuva</th>
<th>Luxembourg/Luxemburg</th>
<th>Magyarország</th>
<th>Malta</th>
<th>Nederland</th>
</tr>
</thead>
<tbody>
<tr>
<td>Janssen-Cilag NV</td>
<td>UAB &quot;JOHNSON &amp; JOHNSON&quot;</td>
<td>Janssen-Cilag NV</td>
<td>Janssen-Cilag Kft.</td>
<td>AM MANGION LTD.</td>
<td>Janssen-Cilag B.V.</td>
</tr>
<tr>
<td>Antwerpseweg 15-17</td>
<td>Geležinio Vilko g. 18A</td>
<td>Antwerpseweg 15-17</td>
<td>Nagyenved u. 8-14</td>
<td>Mangion Building, Triq Ġdida fi Triq Valletta</td>
<td>Graaf Engelbertlaan 75</td>
</tr>
<tr>
<td>B-2340 Beerse</td>
<td>LT-08104 Vilnius</td>
<td>B-2340 Beerse</td>
<td>H-Budapest, 1123</td>
<td>MT-Hal-Luqa LQA 6000</td>
<td>NL-4837 DS Breda</td>
</tr>
<tr>
<td>Tel/Tél: +32 14 64 94 11</td>
<td>Tel: +370 5 278 68 88</td>
<td>Tel: +32 14 64 94 11</td>
<td>Tel.: +36 1 884 2858</td>
<td>Tel: +356 2397 6000</td>
<td>Tel: +31 76 711 1111</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Česká republika</th>
<th>Luxemburg/Luxemburg</th>
<th>Danmark</th>
<th>Deutschland</th>
</tr>
</thead>
<tbody>
<tr>
<td>Janssen-Cilag s.r.o.</td>
<td></td>
<td>Janssen-Cilag A/S</td>
<td>Janssen-Cilag GmbH</td>
</tr>
<tr>
<td>Karla Englše 3201/06</td>
<td></td>
<td>Bregnerodvej 133</td>
<td>Johnson &amp; Johnson Platz 1</td>
</tr>
<tr>
<td>CZ-150 00 Praha 5 - Smichov</td>
<td></td>
<td>DK-3460 Birkerød</td>
<td>D-41470 Neuss</td>
</tr>
<tr>
<td>Tel: +420 227 012 227</td>
<td></td>
<td>Tlf: +45 45 94 82 82</td>
<td>Tel: +49 2137 955-955</td>
</tr>
</tbody>
</table>
This leaflet was last revised in {MM/YYYY}.

Detailed information on this medicine is available on the European Medicines Agency web site:
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or pharmacist.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet
1. What INTELENCE is and what it is used for
2. What you need to know before you take INTELENCE
3. How to take INTELENCE
4. Possible side effects
5. How to store INTELENCE
6. Contents of the pack and other information

1. What INTELENCE is and what it is used for

INTELENCE contains the active substance etravirine. INTELENCE belongs to a group of anti-HIV medicines called non-nucleoside reverse transcriptase inhibitors (NNRTIs).

INTELENCE is a medicine used for the treatment of Human Immunodeficiency Virus (HIV) infection. INTELENCE works by reducing the amount of HIV in your body. This will improve your immune system and reduces the risk of developing illnesses linked to HIV infection.

INTELENCE is used in combination with other anti-HIV medicines to treat adults and children 6 years of age and older who are infected by HIV and who have used other anti-HIV medicines before.

Your doctor will discuss with you which combination of medicines is best for you.

2. What you need to know before you take INTELENCE

Do not take INTELENCE
- if you are allergic to etravirine or any of the other ingredients of this medicine (listed in section 6)
- if you are taking elbasvir/grazoprevir (a medicine to treat hepatitis C infection).

Warnings and precautions
Talk to your doctor or pharmacist before taking INTELENCE.

INTELENCE is not a cure for HIV infection. It is part of a treatment reducing the amount of virus in the blood. You can still pass on HIV when taking this medicine, although the risk is lowered by effective antiretroviral therapy. Discuss with your physician the precautions needed to avoid infecting other people.

People taking INTELENCE may still develop infections or other illnesses associated with HIV infection. You must keep in regular contact with your doctor.
Older people
INTELENCE has only been used in a limited number of patients of 65 years or older. If you belong to this age group, please discuss the use of INTELENCE with your doctor.

Bone problems
Some patients taking combination antiretroviral therapy may develop a bone disease called osteonecrosis (death of bone tissue caused by loss of blood supply to the bone). The length of combination antiretroviral therapy, corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index, among others, may be some of the many risk factors for developing this disease. Signs of osteonecrosis are joint stiffness, aches and pains (especially of the hip, knee and shoulder) and difficulty in movement. If you notice any of these symptoms please inform your doctor.

Tell your doctor about your situation
Make sure that you check the following points and tell your doctor if any of these apply to you.
- Tell your doctor if you develop a rash. If a rash occurs, it usually appears soon after anti-HIV treatment with INTELENCE is started and often disappears within 1 to 2 weeks, even with continued use of the medicine. Occasionally, during INTELENCE treatment, you can experience hypersensitivity reaction (allergic reaction including rash and fever but also swelling of the face, tongue or throat, difficulty in breathing or swallowing) which could be potentially life-threatening. Please contact your doctor immediately if you get a hypersensitivity reaction. Your doctor will advise you how to deal with your symptoms and whether INTELENCE must be stopped. If you have stopped treatment due to a hypersensitivity reaction, you should not restart therapy with INTELENCE.
- Tell your doctor if you have or have had problems with your liver, including hepatitis B and/or C. Your doctor may evaluate how severe your liver disease is before deciding if you can take INTELENCE.
- Tell your doctor immediately if you notice any symptoms of infections. In some patients with advanced HIV infection and a history of opportunistic infection, signs and symptoms of inflammation from previous infections may occur soon after anti-HIV treatment is started. It is believed that these symptoms are due to an improvement in the body’s immune response, enabling the body to fight infections that may have been present with no obvious symptoms.
- In addition to the opportunistic infections, autoimmune disorders (a condition that occurs when the immune system attacks healthy body tissue) may also occur after you start taking medicines for the treatment of your HIV infection. Autoimmune disorders may occur many months after the start of treatment. If you notice any symptoms of infection or other symptoms such as muscle weakness, weakness beginning in the hands and feet and moving up towards the trunk of the body, palpitations, tremor or hyperactivity, please inform your doctor immediately to seek necessary treatment.

Children and adolescents
Do not give this medicine to children less than 6 years of age or weighing less than 16 kg because the potential benefits and risks have not yet been established.

Other medicines and INTELENCE
INTELENCE might interact with other medicines. Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.

In most cases, INTELENCE can be combined with anti-HIV medicines belonging to another class. However, some combinations are not recommended. In other cases, increased monitoring and/or a change in the dose of the medicine may be needed. Therefore, always tell your doctor which other anti-HIV medicines you take. Furthermore, it is important that you carefully read the package leaflets that are provided with these medicines. Follow your doctor’s instruction carefully on which medicines can be combined.
It is not recommended to combine INTELENCE with any of the following medicines:
- tipranavir/ritonavir, efavirenz, nevirapine, ritipivirine, indinavir, nelfinavir, atazanavir/cobicistat, darunavir/cobicistat (anti-HIV medicine)
- carbamazepine, phenobarbital, phenytoin (medicines to prevent seizures)
- rifampicin, because it is contraindicated with boosted protease inhibitors, and rifapentine (medicines to treat some infections such as tuberculosis)
- products that contain St John’s wort (Hypericum perforatum) (a herbal product used for depression)
- daclatasvir, simeprevir (medicines to treat hepatitis C infection).

If you are taking any of these, ask your doctor for advice.

The effects of INTELENCE or other medicines might be influenced if you take INTELENCE together with any of the following medicines. Tell your doctor if you take:
- amiodarone, bepridil, digoxin, disopyramide, flecainide, lidocaine, mexiletine, propafenone and quinidine (medicines to treat certain heart disorders, e.g., abnormal heart beat)
- warfarin (a medicine used to reduce clotting of the blood). Your doctor will have to check your blood
- fluconazole, itraconazole, ketoconazole, posaconazole, voriconazole (medicines to treat fungal infections)
- clarithromycin, rifabutin (antibiotics)
- artemether/lumefantrine (a medicine to treat malaria)
- dexamethasone (a corticosteroid used in a variety of conditions such as inflammation and allergic reactions)
- boceprevir (a medicine to treat hepatitis C infection)
- atorvastatin, fluvastatin, lovastatin, rosuvastatin, simvastatin (cholesterol-lowering medicines)
- cyclosporine, sirolimus, tacrolimus (immunosuppressants)
- sildenafil, vardenafil, tadalafil (medicines to treat erectile dysfunction and/or pulmonary arterial hypertension)
- clopidogrel (a medicine to prevent blood clots).

Pregnancy and breast-feeding
Tell your doctor immediately if you are pregnant. Pregnant women should not take INTELENCE unless specifically directed by the doctor. HIV infected mothers must not breast-feed, as there is a possibility of infecting the baby with HIV.

Driving and using machines
Do not drive or operate machines if you feel sleepy or dizzy after taking your medicines.

3. How to take INTELENCE

Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.

Use in adults
The recommended dose of INTELENCE is one tablet twice a day.
In the morning, take one 200 milligram INTELENCE tablet, following a meal.
In the evening, take one 200 milligram INTELENCE tablet, following a meal.

Use in children and adolescents 6 years of age and older and weighing at least 16 kg
The doctor will work out the right dose based on the weight of the child.
The doctor will inform you exactly how much INTELENCE the child should take.

Do not stop administering INTELENCE without talking to the child’s doctor.
The other HIV medicines used in combination with INTELENCE should be taken by the child as recommended by the child’s doctor.

**Instructions for taking INTELENCE for all patients**

It is important that you take INTELENCE following a meal. If you take INTELENCE on an empty stomach, only half the amount of INTELENCE is absorbed. Follow your doctor’s advice on the type of meal you should be taking with INTELENCE.

Swallow the INTELENCE tablet(s) whole with a glass of water. Do not chew the tablet(s).

- If you are unable to swallow the INTELENCE tablet(s) whole, you may do the following:
  - place the tablet(s) in 5 ml (1 teaspoon) of water, or at least enough liquid to cover the medicine,
  - stir well until the water looks milky,
  - if desired, add more water or alternatively orange juice or milk (do not place the tablets in orange juice or milk without first adding water),
  - drink it immediately,
  - rinse the glass several times with water, orange juice, or milk and completely swallow the rinse each time to make sure you take the entire dose.
- Do not use warm (> 40°C) or carbonated beverages when taking INTELENCE tablet(s).

**Removing the child resistant cap**

The plastic bottle comes with a child resistant cap and should be opened as follows:
- Push the plastic screw cap down while turning it counter clockwise.
- Remove the unscrewed cap.

**If you take more INTELENCE than you should**

Contact your doctor or pharmacist immediately. The most frequent side effects of INTELENCE are rash, diarrhoea, nausea, and headache (see section ‘4. Possible side effects’).

**If you forget to take INTELENCE**

If you notice **within 6 hours of the time you usually take INTELENCE**, you must take the tablet as soon as possible. Always take the tablet following a meal. Then take the next dose as usual. If you notice **after 6 hours**, then skip the intake and take the next doses as usual. Do not take a double dose to make up for a forgotten dose.

**Do not stop taking INTELENCE without talking to your doctor first**

HIV therapy may increase your sense of well-being. Even if you feel better, do not stop taking INTELENCE or your other anti-HIV medicines. Doing so could increase the risk of the virus developing resistance. Talk to your doctor first.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

**4. Possible side effects**

During HIV therapy there may be an increase in weight and in levels of blood lipids and glucose. This is partly linked to restored health and life style, and in the case of blood lipids sometimes to the HIV medicines themselves. Your doctor will test for these changes.

Like all medicines, this medicine can cause side effects, although not everybody gets them.

The frequency rate of the side effects associated with INTELENCE is given below.
Very common side effects (may affect more than 1 in 10 people)
- skin rash. The rash is usually mild to moderate. In rare instances, very serious rash has been reported which can be potentially life-threatening. It is therefore important to contact your doctor immediately if you develop a rash. Your doctor will advise you how to deal with your symptoms and whether INTELENCE must be stopped.

Common side effects (may affect up to 1 in 10 people)
- headache, tingling or pain in hands or feet, numbness, tiredness, sleeplessness, anxiety;
- diarrhoea, nausea, vomiting, heartburn, abdominal pain, inflammation of the stomach, flatulence;
- kidney failure, high blood pressure, heart attack, diabetes;
- night sweats.

Uncommon side effects (may affect up to 1 in 100 people)
- angina, irregular heart rhythm;
- loss of skin sensibility, drowsiness, trembling, fainting, sleepiness, loss of memory, seizures, stroke, disturbance in attention;
- blurred vision, dizziness, sluggishness;
- difficulty breathing;
- dry mouth, mouth inflammation, retching, constipation, distension of the abdomen, inflammation of the pancreas, vomiting blood, decrease of appetite;
- excessive sweating, itching, dry skin, swelling of the face and/or throat;
- allergic reactions (hypersensitivity), symptoms of infection (for example enlarged lymph nodes and fever);
- liver problems such as hepatitis;
- swelling of breasts in men;
- sleep disorders, abnormal dreams, confusion, disorientation, nervousness;

Not known (frequency cannot be estimated from the available data)
- severe hypersensitivity reactions characterised by rash accompanied by fever and organ inflammation such as hepatitis.

Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store INTELENCE

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and on the bottle after EXP. The expiry date refers to the last day of that month.

INTELENCE tablets should be stored in the original bottle. Keep the bottle tightly closed in order to protect from moisture. The bottle contains 3 little pouches (desiccants) to keep the tablets dry. These pouches should stay in the bottle all the time and are not to be eaten.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What INTELENCE contains
- The active substance is etravirine. Each tablet of INTELENCE contains 200 mg of etravirine.
- The other ingredients are hypromellose, silicified microcrystalline cellulose, microcrystalline cellulose, colloidal anhydrous silica, croscarmellose sodium and magnesium stearate.

**What INTELENCE looks like and contents of the pack**
This medicinal product is presented as white to off-white, biconvex, oblong tablet with “T200” on one side.
A plastic bottle containing 60 tablets and 3 pouches to keep the tablets dry.

**Marketing Authorisation Holder**
Janssen-Cilag International NV, Turnhoutseweg 30, B-2340 Beerse, Belgium

**Manufacturer**
Janssen-Cilag SpA, Via C. Janssen, 04100 Borgo San Michele, Latina, Italy

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
<table>
<thead>
<tr>
<th>Country</th>
<th>Company Name</th>
<th>Address</th>
<th>Tel/Fax</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ελλάδα</td>
<td>Janssen-Cilag Φαρμακευτική A.E.B.E.</td>
<td>Δεωφόρος Ειρήνης 56 GR-151 21 Πεύκη, Αθήνα</td>
<td>+30 210 80 90 000</td>
</tr>
<tr>
<td>Österreich</td>
<td>Janssen-Cilag Pharma GmbH</td>
<td>Vorgartenstraße 206B A-1020 Wien</td>
<td>+43 1 610 300</td>
</tr>
<tr>
<td>Polska</td>
<td>Janssen-Cilag Polska Sp. z o.o.</td>
<td>ul. Ilżecka 24 PL-02-135 Warszawa</td>
<td>+48 22 237 60 00</td>
</tr>
<tr>
<td>España</td>
<td>Janssen-Cilag, S.A.</td>
<td>Paseo de las Doce Estrellas, 5-7 E-28042 Madrid</td>
<td>+34 91 722 81 00</td>
</tr>
<tr>
<td>Portugal</td>
<td>Janssen-Cilag Farmacêutica, Lda.</td>
<td>Estrada Consiglieri Pedroso, 69 A Queluz de Baixo PT-2734-503 Barcarena</td>
<td>+351 21 43 68 835</td>
</tr>
<tr>
<td>Polska</td>
<td>Janssen-Cilag Polska Sp. z o.o.</td>
<td>ul. Ilżecka 24 PL-02-135 Warszawa</td>
<td>+48 22 237 60 00</td>
</tr>
<tr>
<td>France</td>
<td>Janssen-Cilag</td>
<td>1, rue Camille Desmoulins, TSA 91003 F-92787 Issy Les Moulineaux, Cedex 9</td>
<td>+33 1 55 00 40 03</td>
</tr>
<tr>
<td>România</td>
<td>Johnson &amp; Johnson România SRL</td>
<td>Str. Tipografilor nr. 11-15 Clădirea S-Park, Corp B3-B4, Etaj 3 013714 Bucureşti, ROMÂNIA</td>
<td>+40 21 207 1800</td>
</tr>
<tr>
<td>Ireland</td>
<td>Janssen-Cilag Ltd.</td>
<td>50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG United Kingdom</td>
<td>+44 1 494 567 444</td>
</tr>
<tr>
<td>Slovenská republika</td>
<td>Johnson &amp; Johnson s.r.o.</td>
<td>CBC III, Karadžičova 12 SK-821 08 Bratislava</td>
<td>+421 232 408 400</td>
</tr>
<tr>
<td>Slovenská republika</td>
<td>Johnson &amp; Johnson s.r.o.</td>
<td>CBC III, Karadžičova 12 SK-821 08 Bratislava</td>
<td>+421 232 408 400</td>
</tr>
<tr>
<td>Portugal</td>
<td>Janssen-Cilag Farmacêutica, Lda.</td>
<td>Estrada Consiglieri Pedroso, 69 A Queluz de Baixo PT-2734-503 Barcarena</td>
<td>+351 21 43 68 835</td>
</tr>
<tr>
<td>Hrvatska</td>
<td>Johnson &amp; Johnson S.E. d.o.o.</td>
<td>Oreškovićeva 6h 10010 Zagreb</td>
<td>+385 1 6610 700</td>
</tr>
<tr>
<td>România</td>
<td>Johnson &amp; Johnson România SRL</td>
<td>Str. Tipografilor nr. 11-15 Clădirea S-Park, Corp B3-B4, Etaj 3 013714 Bucureşti, ROMÂNIA</td>
<td>+40 21 207 1800</td>
</tr>
<tr>
<td>Ireland</td>
<td>Janssen-Cilag Ltd.</td>
<td>50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG United Kingdom</td>
<td>+44 1 494 567 444</td>
</tr>
<tr>
<td>Slovenská republika</td>
<td>Johnson &amp; Johnson s.r.o.</td>
<td>CBC III, Karadžičova 12 SK-821 08 Bratislava</td>
<td>+421 232 408 400</td>
</tr>
<tr>
<td>Italia</td>
<td>Janssen-Cilag SpA</td>
<td>Via M.Buonarroti, 23 I-20093 Cologno Monzese MI</td>
<td>+39 02 2510 1</td>
</tr>
<tr>
<td>Κύπρος</td>
<td>Βαρνάβας Χατζηπαναγής Λτδ,</td>
<td>Λεωφόρος Γιάννου Κρανιδώτη 226 Λατσία CY-2234 Λευκωσία</td>
<td>+357 22 207 700</td>
</tr>
<tr>
<td>Suomi/Finland</td>
<td>Janssen-Cilag Oy</td>
<td>Vaisalantie/Vaisalavägen 2 FI-02130 Espoo/Esbo</td>
<td>+358 207 531 300</td>
</tr>
<tr>
<td>Sverige</td>
<td>Janssen-Cilag AB</td>
<td>Box 4042 SE-16904 Solna</td>
<td>+46 8 626 50 00</td>
</tr>
</tbody>
</table>
This leaflet was last revised in {MM/YYYY}.

Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu/.